

Author index*

A

- Abildgaard U (see Andersen et al). 2003;146:234-41 (Trial design)
 Acquarone N (see Di Lenarda et al). 2003;146:e12
 Acuña M (see Rollán et al). 2003;146:1095-8
 Adamides K (see Michalis et al). 2003;146:304-10
 Adams KF Jr (see Dunlap et al). 2003;146:265-72
 Adams KF Jr (see Lee et al). 2003;146:9-18 (Progress cardi.)
 Adams V (see Erbs et al). 2003;146:280-5
 Aedes PA (see Savage et al). 2003;146:317-23
 Adgey AAJ (see Armstrong et al). 2003;146:484-8
 Adinolfi LE (see Durante Mangoni et al). 2003;146:311-16
 AFFIRM Investigators. Therapeutic strategy in atrial fibrillation. 2003;146:e25 (Letter reply)
 AFIRMAR Study Investigators (see Piegas et al). 2003;146:331-8
 Aharonian VJ (see Kojoglanian et al). 2003;146:1077-81
 Ahern T (see Vollmann et al). 2003;146:1066-70
 Ajani A (see Leborgne et al). 2003;146:501-6
 Ajani AE (see Cheneau et al). 2003;146:142-5
 Akehi N (see Kinjo et al). 2003;146:324-30
 Akita H (see Iwai et al). 2003;146:106-9
 Alam M, Hedman A, Nordlander R, Samad B. Right ventricular function before and after an uncomplicated coronary artery bypass graft as assessed by pulsed wave Doppler tissue imaging of the tricuspid annulus. 2003;146:520-6
 Alexander J (see Sinnaeve et al). 2003;146:27-32
 Alexander JH, Patel MR. Screening for structural heart disease: time to stop listening and start looking. 2003;146:570-1 (Editorial)
 Alexander KP, Biswas MS. Heart failure and the elderly: disease diversity, data, and delivery of care. 2003;146:194-6 (Editorial)
 Alexander M (see Ansari et al). 2003;146:115-20
 Alfonso F (see Moreno et al). 2003;146:e6 (Letter)
 Allen AS (see Hauser and Allen). 2003;146:929-31 (Editorial)
 Allen JD (see Cobb et al). 2003;146:572-80 (Editorial)
 Allen LaPointe NM, Chen A, Hammill B, DeLong E, Kramer JM, Califf RM. Evaluation of the dofetilide risk-management program. 2003;146:894-901
 Allen Maycock CA (see Muhlestein et al). 2003;146:351-8
 Alpert JS. Defining myocardial infarction: "Will the real myocardial infarction please stand up?". 2003;146:377-9 (Editorial)
 Alter DA. Are some patients in Canada treated more equally than others? The Orwell prophecy. 2003;146:938-40 (Editorial)
 Amado JA (see Berrazuela et al). 2003;146:e14
 Ambrosio GB (see Di Lenarda et al). 2003;146:e12
 Andersen HR, Nielsen TT, Vesterlund T, Grande P, Abildgaard U, Thyssen P, Pedersen F, Mortensen LS, DANAMI-2 Investigators. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2). 2003;146:234-41 (Trial design)
 Anderson FP (see Kontos et al). 2003;146:446-52
 Anderson JL (see Carlquist et al). 2003;146:1007-14
 Anderson JL (see Muhlestein et al). 2003;146:351-8
 Andreana A (see Durante Mangoni et al). 2003;146:311-16
 Andrikopoulos GK (see Michaelides et al). 2003;146:160-7
 Andrikopoulos GK (see Zairis et al). 2003;146:1082-9
 Angelucci D (see Di Napoli et al). 2003;146:1105-11
 Annicchiarico M (see Di Lenarda et al). 2003;146:e12
 Ansari M, Alexander M, Tutar A, Massie BM. Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function. 2003;146:115-20
 Ansari M, Massie BM. Heart failure: how big is the problem? Who are the patients? What does the future hold? 2003;146:1-4 (Editorial)

*July, pp. 1-188; August, pp. 189-376; September, pp. 377-560; October, part 1, pp. 561-746; part 2, pp. 51-530; November pp. 747-928; December, pp. 929-1146.

- Antman EM. Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. 2003;146:S18-22
 Antman EM. Low molecular weight heparins for acute coronary syndrome: tackling the issues head-on. 2003;146:191-3 (Editorial)
 Antman EM (see Ferguson et al). 2003;146:628-34
 Antman EM (see Murphy et al). 2003;146:42-7
 Antman EM (see Spinler et al). 2003;146:33-41
 Ardissino D (see Sinnaeve et al). 2003;146:27-32
 Arheden H (see Engblom et al). 2003;146:359-66
 Arjomand H, Turi ZG, McCormick D, Goldberg S. Percutaneous coronary intervention: historical perspectives, current status, and future directions. 2003;146:787-96 (Curriculum cardi.)
 Armstrong P (see Sinnaeve et al). 2003;146:27-32
 Armstrong PW, Burton J, Pakola S, Mollhoek PG, Betriu A, Tendera M, Bode C, Adgey AAJ, Bar F, Vahanian A, Van de Werf F, CAPTORS II Investigators. Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II). 2003;146:484-8
 Armstrong PW (see Lockwood et al). 2003;146:640-5
 Aronson D (see Goldberg et al). 2003;146:819-23
 Asch DA (see Halpern et al). 2003;146:985-92 (Trial design)
 ASSENT-2 Investigators (see Lockwood et al). 2003;146:640-5
 ASSENT-2 Investigators (see Sinnaeve et al). 2003;146:27-32
 Assmann SF (see French et al). 2003;146:804-10
 Avezum A (see Budaj et al). 2003;146:999-1006
 Avezum A (see Piegas et al). 2003;146:331-8
 Aviles RJ (see Kopecky et al). 2003;146:146-52
 Awata N (see Takeda et al). 2003;146:175-82
 Ayanian JZ. Is geography destiny? Illuminating the survival advantage of elderly patients in New England after acute myocardial infarction. 2003;146:207-9 (Editorial)
 Azimilide Supraventricular Arrhythmia Program Investigators (see Connolly et al). 2003;146:489-93

B

- Babiyak MA (see Jiang et al). 2003;146:55-61
 Bahler RC (see Baker et al). 2003;146:736-40
 Bahr R (see Roe et al). 2003;146:993-8
 Bair TL (see Carlquist et al). 2003;146:1007-14
 Bair TL (see Muhlestein et al). 2003;146:351-8
 Baither Y (see Erbs et al). 2003;146:280-5
 Baker DW, Bahler RC, Finkelhor RS, Lauer MS. Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure. 2003;146:736-40
 Baker DW, Einstadter D, Thomas C, Cebul RD. Mortality trends for 23,505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997. 2003;146:258-64
 Bakhai A (see Leon and Bakhai). 2003;146:S13-17
 Balbone A (see Di Napoli et al). 2003;146:1105-11
 Ballantyne CM, Blazing MA, Hunninghake DB, Davidson MH, Yuan Z, DeLuca P, Ramsey KE, Hustad CM, Palmisano J. Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). 2003;146:862-9
 Ballantyne CM, Hoogeveen RC. Role of lipid and lipoprotein profiles in risk assessment and therapy. 2003;146:227-33 (Progress cardi.)
 Banham D (see Cheek et al). 2003;146:978-84 (Trial design)
 Bar F (see Armstrong et al). 2003;146:484-8
 Barbieri A (see Grigioni et al). 2003;146:298-303
 Barlera S (see Guazzi et al). 2003;146:542-8
 Barron HV (see Krumholz et al). 2003;146:839-47
 Barsness G (see Linnemeier et al). 2003;146:453-8
 Barsotti A (see Di Napoli et al). 2003;146:1105-11
 Barton F (see Herd et al). 2003;146:273-9
 Barton FB (see Lindquist et al). 2003;146:1038-44

- Bashore TM (see Krasuski et al). 2003;146:1099-104
- Bates ER (see Ferguson et al). 2003;146:628-34
- Batika PC (see Zairis et al). 2003;146:1082-9
- Battler A (see Hasdai et al). 2003;146:832-8
- Bazzino OO (see Berrocal et al). 2003;146:e22
- Becker RC (see Kim and Becker). 2003;146:948-57 (Curriculum cardiol.)
- Behar S (see Hasdai et al). 2003;146:832-8
- Behling A, Moraes RS, Rohde LE, Ferlin EL, Nóbrega ACL, Ribeiro JP. Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure. 2003;146:494-500
- Behrens S (see Müller et al). 2003;146:1061-5
- Beinart SC, Sales AE, Spertus JA, Plomondon ME, Every NR, Rumsfeld JS. Impact of angina burden and other factors on treatment satisfaction after acute coronary syndromes. 2003;146:646-52
- Bélisle P (see Pilote et al). 2003;146:1030-7
- Bell MR (see Best et al). 2003;146:345-50
- Bell MR (see Kopecky et al). 2003;146:146-52
- Bell SS (see Hedén et al). 2003;146:797-803 (Curriculum cardiol.)
- Bellis P (see Di Lenarda et al). 2003;146:e12
- Bellotti P (see Di Lenarda et al). 2003;146:e12
- Belmans A (see Sinnaeve et al). 2003;146:27-32
- Beltrame JF, Limaye SB, Wuttke RD, Horowitz JD. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. 2003;146:84-90
- Beltrame JF, Turner SP, Leslie S, Horowitz JD. Mibefradil: "has the baby been thrown out with the bath water?". 2003;146:e3 (Letter)
- Ben MG (see Berrocal et al). 2003;146:e22
- Berger PB (see Best et al). 2003;146:345-50
- Berlin JA (see Halpern et al). 2003;146:985-92 (Trial design)
- Berrazueta JR, Sampedro I, Garcia-Unzueta T, Llorca J, Bustamante M, Amado JA. Effect of transdermal nitroglycerin on inflammatory mediators in patients with peripheral atherosclerotic vascular disease. 2003;146:e14
- Berrocal DH, Cohen MG, Spinetta AD, Ben MG, Matas CAR, Gabay JM, Magni JM, Nogareda G, Oberti P, Von Schulz C, Doval H, Bazzino OO, Cagide A, Oliveri R, Grinfeld LR. Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase. 2003;146:e22
- Bersot TP, Pépin GM, Mahley RW. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol. 2003;146:1052-60
- Bertocchi F (see De Tommasi et al). 2003;146:e17
- Best LG (see Devereux et al). 2003;146:527-34
- Best PJM, Lennon R, Gersh BJ, Ting HH, Rihal CS, Bell MR, Herzog CA, Holmes DR Jr, Berger PB. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. 2003;146:345-50
- Besta F (see Massberg et al). 2003;146:e19
- Betriu A (see Armstrong et al). 2003;146:484-8
- Beyar R (see Goldberg et al). 2003;146:819-23
- Bhatt DL (see Gurm et al). 2003;146:692-8
- Bianchi F (see Latini et al). 2003;146:e2
- Biddle WP (see Oldemeyer et al). 2003;146:e23
- Billgren T (see Engblom et al). 2003;146:359-66
- Binner L (see Vollmann et al). 2003;146:1066-70
- Biswas MS (see Al-Khatib and Biswas). 2003;146:944-5 (Editorial)
- Biswas MS (see Alexander and Biswas). 2003;146:194-6 (Editorial)
- Bittner V (see Hsia et al). 2003;146:439-45
- Bittner V (see Shlipak et al). 2003;146:870-5
- Bittner V (see Wu et al). 2003;146:129-33
- Blazing MA, Crawford LE. Enhanced External Counterpulsation (EECP): enough evidence to support this and the next wave? 2003;146:383-4 (Editorial)
- Blazing MA (see Ballantyne et al). 2003;146:862-9
- Bliden KP (see Gurbel and Bliden). 2003;146:e10
- Blumenthal JA (see Jiang et al). 2003;146:55-61
- Blumenthal JA (see Watkins et al). 2003;146:48-54
- Blumenthal RS (see Nasir et al). 2003;146:969-77 (Progress cardiol.)
- Bode C (see Armstrong et al). 2003;146:484-8
- Bode C (see Schmidt et al). 2003;146:908-13
- Boden WE (see Januzzi et al). 2003;146:764-74 (Curriculum cardiol.)
- Boersma E (see Lamfers et al). 2003;146:479-83
- Bogaerts K (see Sinnaeve et al). 2003;146:27-32
- Boland J (see French et al). 2003;146:804-10
- Borges-Neto S (see Bourque et al). 2003;146:621-7
- Boriani G (see Grigioni et al). 2003;146:298-303
- Böttiger C, Koch W, Lahn C, Mehili J, von Beckerath N, Schömig A, Kastrati A. 4G/5G Polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. 2003;146:855-61
- Bourque JM, Hasselblad V, Velazquez EJ, Borges-Neto S, O'Connor CM. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. 2003;146:621-7
- Boyko V (see Hasdai et al). 2003;146:832-8
- Bragdon EE (see Sheps and Bragdon). 2003;146:197-8 (Editorial)
- Branzi A (see Grigioni et al). 2003;146:298-303
- Bratos JL (see Rollán et al). 2003;146:1095-8
- Braunwald E (see Murphy et al). 2003;146:42-7
- Brieger D (see Budaj et al). 2003;146:999-1006
- Brilakis ES, Wright RS, Kopecky SL, Mavrogiorgos NC, Reeder GS, Rihal CS, Gersh BJ, Williams BA, Clements IP. Association of the PURSUIT risk score with predischARGE ejection fraction, angiographic severity of coronary artery disease, and mortality in a nonselected, community-based population with non-ST-elevation acute myocardial infarction. 2003;146:811-18
- Brindis RG, Weintraub WS, Dudley RA. Volume as a surrogate for percutaneous coronary intervention quality: is this the right measuring stick? 2003;146:932-4 (Editorial)
- Brindis RG (see Roe et al). 2003;146:605-12 (Progress cardiol.)
- Brochu M (see Savage et al). 2003;146:317-23
- Brosteau O (see Sick et al). 2003;146:134-41
- Brouwer IA (see Geelen et al). 2003;146:e4
- Brown DL. Analysis of the institutional volume-outcome relations for balloon angioplasty and stenting in the stent era in California. 2003;146:1071-6
- Brown WV (see Herrington et al). 2003;146:662-7
- Brunner M (see Schmidt et al). 2003;146:908-13
- Bryson CL (see Mozaffarian et al). 2003;146:1015-22
- Budaj A, Brieger D, Gabriel Steg P, Goodman SG, Dabbous OH, Fox KAA, Avezum A, Cannon CP, Mazurek T, Flather MD, Van De Werf F, GRACE Investigators. Global patterns of use of anti-thrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). 2003;146:999-1006
- Budoff MJ (see Nasir et al). 2003;146:969-77 (Progress cardiol.)
- Budoff MJ (see Yamamoto et al). 2003;146:153-9
- Bühning M (see Michalsen et al). 2003;146:e11
- Buller CE (see French et al). 2003;146:804-10
- Burchette RJ (see Kojouharian et al). 2003;146:1077-81
- Burton J (see Armstrong et al). 2003;146:484-8
- Bush A (see Krasuski et al). 2003;146:1099-104
- Bustamante M (see Berrazueta et al). 2003;146:e14

C

- Cabell CH, Fowler VG Jr. Vegetations in endocarditis: big is bad, but is there more to it? 2003;146:189-90 (Editorial)
- Cafiero M (see Di Lenarda et al). 2003;146:e12
- Cagide A (see Berrocal et al). 2003;146:e22
- Calafiore AM (see Di Napoli et al). 2003;146:1105-11
- Califf RM (see Allen LaPointe et al). 2003;146:894-901
- Califf RM (see Roe et al). 2003;146:605-12 (Progress cardiol.)
- Calori G (see Fragasso et al). 2003;146:e18
- Canby RC (see Vollmann et al). 2003;146:1066-70
- Cannon CP (see Budaj et al). 2003;146:999-1006

- Cannon CP (see Januzzi et al). 2003;146:764-74 (Curriculum cardiol.)
- Canos D (see Leborgne et al). 2003;146:501-6
- Cantley LK (see Goff et al). 2003;146:1045-51
- CAPTORS II Investigators (see Armstrong et al). 2003;146:484-8
- Carayon A (see Isnard et al). 2003;146:729-35
- Cardano P (see Guazzi et al). 2003;146:542-8
- Carigi S (see Grigioni et al). 2003;146:298-303
- Carlquist JF, Muhlestein JB, Horne BD, Hart NI, Bair TL, Molhuizen HOF, Anderson JL. The cholesteryl ester transfer protein *Taq1B* gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. 2003;146:1007-14
- Carlquist JF (see Muhlestein et al). 2003;146:351-8
- Carstens JS (see Deutschman et al). 2003;146:62-8
- Casaret D (see Halpern et al). 2003;146:985-92 (Trial design)
- Cattellier D (see Watkins et al). 2003;146:48-54
- Cebul RD (see Baker et al). 2003;146:258-64
- Cecconi C (see De Tommasi et al). 2003;146:e17
- Ceska R (see Melenovsky et al). 2003;146:e1
- Ceska R (see Stulc et al). 2003;146:e21
- Chafirovskaa O (see Isnard et al). 2003;146:729-35
- Chang SM, Sekandrzd MW, Jiang S, Nagueh S, Spencer W III, Lakkis N. Impact of infarct size on clinical and echocardiographic outcome in patients undergoing nonsurgical septal reduction therapy. 2003;146:1112-14
- Chaput LA (see Shlipak et al). 2003;146:870-5
- Chen A (see Allen LaPointe et al). 2003;146:894-901
- Chen J (see Krumholz et al). 2003;146:242-9
- Cheneau E, Wu Z, Leborgne L, Ajani AE, Weissman N, Pichard AD, Satler LF, Kent KM, Mintz G, Waksman R. Additional stenting promotes intimal proliferation and compromises the results of intravascular radiation therapy: an intravascular ultrasound study. 2003;146:142-5
- Cheneau E (see Leborgne et al). 2003;146:501-6
- Cheng TO. Hiccup as an electrocardiographic artifact simulating arrhythmias. 2003;146:e15 (Letter)
- Cheok F, Schrader G, Banham D, Marker J, Hordacre A-L. Identification, course, and treatment of depression after admission for a cardiac condition: rationale and patient characteristics for the Identifying Depression As a Comorbid Condition (IDACC) project. 2003;146:978-84 (Trial design)
- Choi K (see Ricciardi et al). 2003;146:507-12
- Christ M (see Grimm et al). 2003;146:372-6
- Christenson RH (see Roe et al). 2003;146:605-12 (Progress cardiol.), 993-8
- Christian TF (see Hedén et al). 2003;146:797-803 (Curriculum cardiol.)
- Chugh SS, Chung K, Zheng Z-J, John B, Titus JL. Cardiac pathologic findings reveal a high rate of sudden cardiac death of undetermined etiology in younger women. 2003;146:635-9
- Chung K (see Chugh et al). 2003;146:635-9
- Cichowski E (see Oldemeyer et al). 2003;146:e23
- Cleland JGF (see McGowan and Cleland). 2003;146:388-97 (Curriculum cardiol.)
- Clements IP (see Brilakis et al). 2003;146:811-18
- Clemmensens P (see Jurlander et al). 2003;146:757-63 (Progress cardiol.)
- Cobb FR, Kraus WE, Root M, Allen JD. Assessing risk for coronary heart disease: beyond Framingham. 2003;146:572-80 (Editorial)
- Coccolo F (see Grigioni et al). 2003;146:298-303
- Cohen HA, Williams DO, Holmes DR Jr, Selzer F, Kip KE, Johnston JM, Holubkov R, Kelsey SF, Detre KM. Impact of age on procedural and 1-year outcome in percutaneous transluminal coronary angioplasty: a report from the NHLBI Dynamic Registry. 2003;146:513-19
- Cohen M (see Ferguson et al). 2003;146:628-34
- Cohen M (see Spinler et al). 2003;146:33-41
- Cohen MG (see Berrocal et al). 2003;146:e22
- Cohen SJ (see Goff et al). 2003;146:1045-51
- Cohn JN, Hoke L, Whitwam W, Sommers PA, Taylor AL, Duprez D, Roessler R, Florea N. Screening for early detection of cardiovascular disease in asymptomatic individuals. 2003;146:679-85
- Cole D (see Smith et al). 2003;146:69-74
- Coleman RE (see Jiang et al). 2003;146:55-61
- Connolly SJ, Schnell DJ, Page RL, Wilkinson WE, Marcello SR, Pritchett ELC, Azimilide Supraventricular Arrhythmia Program Investigators. Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. 2003;146:489-93
- Coronary Care Unit Group (see Tedesco et al). 2003;146:472-8
- Cramer M-JM (see De Boeck et al). 2003;146:411-19 (Progress cardiol.)
- Crawford LE (see Blazing and Crawford). 2003;146:383-4 (Editorial)
- Cremonesi G (see Latini et al). 2003;146:e2
- Criger DA (see Sadanandan et al). 2003;146:653-61
- Cropp AS (see Wijeysondera et al). 2003;146:291-7
- Crowley A, Menon V, Lessard D, Yarbzebski J, Jackson E, Gore JM, Goldberg RJ. Sex differences in survival after acute myocardial infarction in patients with diabetes mellitus (Worcester Heart Attack Study). 2003;146:824-31
- Czajkowski S (see Lindquist et al). 2003;146:1038-44
- Czajkowski SM (see Herd et al). 2003;146:273-9
- Czuriga I (see Jánosi et al). 2003;146:721-8
- D**
- Dabbous OH (see Budaj et al). 2003;146:999-1006
- DANAMI-2 Investigators (see Andersen et al). 2003;146:234-41 (Trial design)
- Dauterman K (see Murphy et al). 2003;146:42-7
- Davidson CJ (see Ricciardi et al). 2003;146:507-12
- Davidson MH (see Ballantyne et al). 2003;146:862-9
- Davis W (see Herrington et al). 2003;146:662-7
- De Boeck BWL, Cramer M-JM, Oh JK, van der Aa RPLM, Jaarsma W. Spectral pulsed tissue Doppler imaging in diastole: a tool to increase our insight in and assessment of diastolic relaxation of the left ventricle. 2003;146:411-19 (Progress cardiol.)
- De Caterina R, Madonna R, Zucchi R, La Rovere MT. Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. 2003;146:420-30 (Progress cardiol.)
- De Caterina R (see Di Napoli et al). 2003;146:1105-11
- de Lemos JA, Morrow DA. Noninvasive assessment of reperfusion therapy: slow progress toward a worthwhile goal. 2003;146:747-9 (Editorial)
- de Lemos JA (see Murphy et al). 2003;146:42-7
- De Maria R (see Di Lenarda et al). 2003;146:e12
- De Tommasi E, Iacoviello M, Romito R, Cecconi C, Guida P, Massari F, Francolini G, Bertocchi F, Ferrarri R, Rizzon P, Pitzalis MV. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. 2003;146:e17
- De Vita S (see Guazzi et al). 2003;146:542-8
- Delapril Remodeling after Acute Myocardial Infarction (DRAM) Collaborative Group (see Latini et al). 2003;146:e2
- Dellborg M (see Herlitz et al). 2003;146:1023-9
- DeLong E (see Allen LaPointe et al). 2003;146:894-901
- DeLucca P (see Ballantyne et al). 2003;146:862-9
- Dery J-P (see Petersen et al). 2003;146:19-26 (Meetings)
- Detre KM (see Cohen et al). 2003;146:513-19
- Deutschman DH, Carstens JS, Klepper RL, Smith WS, Page MT, Young TR, Gleason LA, Nakajima N, Sabbadini RA. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. 2003;146:62-8
- Devereux RB, Roman MJ, Palmieri V, Liu JE, Lee ET, Best LG, Fabsitz RR, Rodcheffer RJ, Howard BV. Prognostic implications of ejection fraction from linear echocardiographic dimensions: the Strong Heart Study. 2003;146:527-34
- Dhalla NS (see Wijeysondera et al). 2003;146:291-7

- Di Lenarda A, Scherillo M, Maggioni AP, Acquareone N, Ambrosio GB, Annicchiarico M, Bellis P, Bellotti P, De Maria R, Laveccchia R, Lucci D, Mathieu G, Opasich C, Porcu M, Tavazzi L, Cafiero M, TEMISTOCLE Investigators. Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds—the TEMISTOCLE study. 2003;146:e12
- Di Napoli P, Taccardi AA, Grilli A, Felaco M, Balbone A, Angelucci D, Gallina S, Calafiore AM, De Caterina R, Barsotti A. Left ventricular wall stress as a direct correlate of cardiomyocyte apoptosis in patients with severe dilated cardiomyopathy. 2003;146:1105-11
- Diamond E (see Goldberg et al). 2003;146:819-23
- Diaz R (see Sinnaeve et al). 2003;146:27-32
- Diez Roux AV (see Ding et al). 2003;146:459-64
- Dilaveris PE (see Michaelides et al). 2003;146:160-7
- Ding J, Diez Roux AV, Nieto FJ, McNamara RL, Hetmanski JB, Taylor HA Jr, Tyroler HA. Racial disparity in long-term mortality rate after hospitalization for myocardial infarction: the Atherosclerosis Risk in Communities study. 2003;146:459-64
- Dirschinger J (see Hausleiter et al). 2003;146:882-6
- Dobos GJ (see Michalsen et al). 2003;146:e11
- Donath D (see Sheppard et al). 2003;146:775-86 (Curriculum cardiol.)
- Dotzer F (see Hausleiter et al). 2003;146:882-6
- Doval H (see Berrocal et al). 2003;146:e22
- Dudley RA (see Brindis et al). 2003;146:932-4 (Editorial)
- Dunlap SH, Mallemala S, Sueti CA, Schwartz TA, Adams KF Jr. Survival rates are similar between African American and white patients with heart failure. 2003;146:265-72
- Duprez D (see Cohn et al). 2003;146:679-85
- Dupuis G (see Herd et al). 2003;146:273-9
- Dupuis G (see Lindquist et al). 2003;146:1038-44
- Durante Mangoni E, Adinolfi LE, Tripodi M-F, Andreana A, Gambardella M, Ragone E, Precone DF, Utili R, Ruggiero G. Risk factors for "major" embolic events in hospitalized patients with infective endocarditis. 2003;146:311-16
- Duval S (see Herlitz et al). 2003;146:1023-9
- Dvorak D (see Tedesco et al). 2003;146:472-8

E

- Eagle KA (see Mukherjee and Eagle). 2003;146:946-7 (Editorial)
- EARLY Investigators (see Roe et al). 2003;146:993-8
- Eckart RE (see Shry et al). 2003;146:1090-4
- Einstadter D (see Baker et al). 2003;146:258-64
- Eisenberg MJ (see Sheppard et al). 2003;146:775-86 (Curriculum cardiol.)
- Ellis SG (see Gurm et al). 2003;146:692-8
- Emergency Medicine Cardiac Research and Education Group (EM-CREG) (see Roe et al). 2003;146:993-8
- Engblom H, Wagner GS, Setser RM, Selvester RH, Billgren T, Kasper JM, Maynard C, Pahlm O, Arheden H, White RD. Quantitative clinical assessment of chronic anterior myocardial infarction with delayed enhancement magnetic resonance imaging and QRS scoring. 2003;146:359-66
- ENRICH Investigators (see Watkins et al). 2003;146:48-54
- Erbs S, Gielen S, Linke A, Möbius-Winkler S, Adams V, Baithier Y, Schuler G, Hambrecht R. Improvement of peripheral endothelial dysfunction by acute vitamin C application: different effects in patients with coronary artery disease, ischemic, and dilated cardiomyopathy. 2003;146:280-5
- Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. 2003;146:581-90 (Curriculum cardiol.)
- ESSENCE Investigators (see Spinler et al). 2003;146:33-41
- Esteves JP (see Piegas et al). 2003;146:331-8
- Eto Y (see Shin et al). 2003;146:914-19
- Every NR (see Beinart et al). 2003;146:646-52
- Every NR (see Ferguson et al). 2003;146:628-34
- Every NR (see Krumholz et al). 2003;146:839-47
- Exadaktylos NI (see Michaelides et al). 2003;146:160-7

F

- Faber TS (see Schmidt et al). 2003;146:908-13
- Fabsitz RR (see Devereux et al). 2003;146:527-34
- Farran JA (see Piegas et al). 2003;146:331-8
- Fattoruto M. Measurement of the effect of ticlopidine with the platelet function analyser (PFA-100) during coronary stent implantation. 2003;146:e8 (Letter)
- Fauchier JP (see Fauchier and Fauchier). 2003;146:e24 (Letter)
- Fauchier L, Fauchier JP. Therapeutic strategy in atrial fibrillation. 2003;146:e24 (Letter)
- Feinglass J, Martin GJ, Lin E, Johnson MR, Gheorghiadu M. Is heart failure survival improving? Evidence from 2323 elderly patients hospitalized between 1989–2000. 2003;146:111-14
- Felaco M (see Di Napoli et al). 2003;146:1105-11
- Feldman HA (see French et al). 2003;146:804-10
- Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction: clinical strategies for treating oxidant stress. 2003;146:218-26 (Curriculum cardiol.)
- Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P, NICE-3 Investigators. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. 2003;146:628-34
- Ferlin EL (see Behling et al). 2003;146:494-500
- Ferrari R (see De Tommasi et al). 2003;146:e17
- Fesmire FM (see Roe et al). 2003;146:993-8
- Fialová L (see Stulc et al). 2003;146:e21
- Fihn SD (see Mozaffarian et al). 2003;146:1015-22
- Finkelhor RS (see Baker et al). 2003;146:736-40
- Finsterer J (see Stöcklberger et al). 2003;146:e26 (Letter)
- Fischer H (see Yamamoto et al). 2003;146:153-9
- Fischi MC (see Petersen et al). 2003;146:19-26 (Meetings)
- Fishman EK (see Nasir et al). 2003;146:969-77 (Progress cardiol.)
- Flaker G, Greenspon A, Tardiff B, Schron E, Goldman L, Hellkamp A, Lee K, Lamas G, Mode Selection Trial (MOST) Investigators. Death in patients with permanent pacemakers for sick sinus syndrome. 2003;146:887-93
- Flather MD (see Budaj et al). 2003;146:999-1006
- Fleming J (see Krasuski et al). 2003;146:1099-104
- Florean N (see Cohn et al). 2003;146:679-85
- Foussas SG (see Zairis et al). 2003;146:1082-9
- Fowler VG Jr (see Cabell and Fowler). 2003;146:189-90 (Editorial)
- Fox KAA (see Budaj et al). 2003;146:999-1006
- Fragasso G, Piatti PM, Monti L, Palloschi A, Setola E, Puccetti P, Calori G, Lepaschuk GD, Margonato A. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. 2003;146:e18
- Francolini G (see De Tommasi et al). 2003;146:e17
- Frank TA (see Goldberg et al). 2003;146:705-12
- Fraulo ES (see Roe et al). 2003;146:993-8
- Fredericks S (see Smith et al). 2003;146:69-74
- Freedland KE (see Kerzner et al). 2003;146:286-90
- Freedland KE (see Watkins et al). 2003;146:48-54
- French JK, Feldman HA, Assmann SF, Sanborn T, Palmeri ST, Miller D, Boland J, Buller CE, Steingart R, Sleeper LA, Hochman JS, SHOCK Investigators. Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on a 12-month survival in the SHOCK trial. 2003;146:804-10
- Fretz DE (see Ziakas et al). 2003;146:699-704
- Frison L (see Gombert-Maitland et al). 2003;146:398-403 (Curriculum cardiol.)
- Fritz LM (see Kontos et al). 2003;146:446-52
- Frommelt G (see Kopecky et al). 2003;146:146-52
- Fu Y (see Lockwood et al). 2003;146:640-5
- Furgerson JL (see Shry et al). 2003;146:1090-4

G

- Gabay JM (see Berrocal et al). 2003;146:e22
Gabriel Steg P (see Budaj et al). 2003;146:999-1006
Gage BF (see Kerzner et al). 2003;146:286-90
Galatius S (see Jurlander et al). 2003;146:757-63 (Progress cardi-
ol.)
Galiñanes M (see Sensky et al). 2003;146:e13
Gallina S (see Di Napoli et al). 2003;146:1105-11
Gambardella M (see Durante Mangoni et al). 2003;146:311-16
Garcia-Unzueta T (see Berrazueta et al). 2003;146:e14
Gattis W (see Lee et al). 2003;146:9-18 (Progress cardi-
ol.)
Gawaz M (see Massberg et al). 2003;146:e19
Geelen A, Zock PL, Swenne CA, Brouwer LA, Schouten EG, Katan
MB. Effect of n-3 fatty acids on heart rate variability and barore-
flex sensitivity in middle-aged subjects. 2003;146:e4
Genest J Jr (see Essebag et al). 2003;146:581-90 (Curriculum car-
diol.)
Georgiade M (see Feinglass et al). 2003;146:111-14
Geraci E (see Latini et al). 2003;146:e2
Gerrits B (see Vollmann et al). 2003;146:1066-70
Gersh BJ (see Best et al). 2003;146:345-50
Gersh BJ (see Brilakis et al). 2003;146:811-18
Gertz BJ (see Weir et al). 2003;146:591-604 (Progress cardi-
ol.)
Ghali J (see Wijeyesundera et al). 2003;146:291-7
Ghali JK (see Jánosi et al). 2003;146:721-8
Gheorghiadu M (see Lee et al). 2003;146:9-18 (Progress cardi-
ol.)
Gibbons RJ (see Kopecky et al). 2003;146:146-52
Gibler WB (see Roe et al). 2003;146:605-12 (Progress cardi-
ol.)
Gibson CM (see Murphy et al). 2003;146:42-7
Gielen S (see Erbs et al). 2003;146:280-5
Giesler U (see Schmidt et al). 2003;146:908-13
Gilbert RE (see Haas et al). 2003;146:848-53
Gleason LA (see Deutschman et al). 2003;146:62-8
Goff DC Jr, Gu L, Cantley LK, Sheedy DJ, Cohen SJ. Quality of care
for secondary prevention for patients with coronary heart dis-
ease: results of the Hastening the Effective Application of Re-
search through Technology (HEART) trial. 2003;146:1045-51
Goldberg A, Zinder O, Zdoroviyak A, Diamond E, Lischinsky S,
Gruberg L, Markiewicz W, Beyar R, Aronson D. Diagnostic
coronary angiography induces a systemic inflammatory re-
sponse in patients with stable angina. 2003;146:819-23
Goldberg LR, Piette JD, Walsh MN, Frank TA, Jaski BE, Smith AL,
Rodriguez R, Mancini DM, Hopton LA, Orav EJ, Loh E, WHARF
Investigators. Randomized trial of a daily electronic home mon-
itoring system in patients with advanced heart failure: the
Weight Monitoring in Heart Failure (WHARF) trial. 2003;146:
705-12
Goldberg RJ (see Crowley et al). 2003;146:824-31
Goldberg S (see Arjormand et al). 2003;146:787-96 (Curriculum
cardiol.)
Goldenberg I (see Lindquist et al). 2003;146:1038-44
Goldman L (see Flaker et al). 2003;146:887-93
Goldschmidt-Clermont PJ. Loss of bone marrow-derived vascular
progenitor cells leads to inflammation and atherosclerosis.
2003;146:S5-12
Gomberg-Maitland M, Frison L, Halperin JL. Active-control clinical
trials to establish equivalence or noninferiority: methodological
and statistical concepts linked to quality. 2003;146:398-403
(Curriculum cardi-ol.)
Goodman SG (see Budaj et al). 2003;146:999-1006
Goodman SG (see Lockwood et al). 2003;146:640-5
Goodman SG (see Spinler et al). 2003;146:33-41
Goodreau L (see Ricciardi et al). 2003;146:507-12
Gore JM (see Crowley et al). 2003;146:824-31
Gouvevenos J (see Michalis et al). 2003;146:304-10
Gowda RM, Khan IA, Nair CK, Mehta NJ, Vasavada BC, Sacchi
TJ. Cardiac papillary fibroelastoma: a comprehensive analysis of
725 cases. 2003;146:404-10 (Curriculum cardi-ol.)
GRACE Investigators (see Budaj et al). 2003;146:999-1006
Gramenzi S (see Latini et al). 2003;146:e2

- Grande P (see Andersen et al). 2003;146:234-41 (Trial design)
Grande P (see Jurlander et al). 2003;146:757-63 (Progress cardi-
ol.)
Granger CB (see Lockwood et al). 2003;146:640-5
Granger CB (see Waters et al). 2003;146:958-68 (Curriculum car-
diol.)
Grauova B (see Melenovsky et al). 2003;146:e1
Gray M-E (see Meier-Ewert et al). 2003;146:339-44
Greenspon A (see Flaker et al). 2003;146:887-93
Grigioni F, Barbieri A, Magnani G, Potena L, Coccolo F, Boriani G,
Specchia S, Carigi S, Musuraca A, Zannoli R, Magelli C, Branzi A.
Serial versus isolated assessment of clinical and instrumental
parameters in heart failure: prognostic and therapeutic implica-
tions. 2003;146:298-303
Grilli A (see Di Napoli et al). 2003;146:1105-11
Grimm RA (see Schwartzman et al). 2003;146:535-41
Grimm W, Rudolph S, Christ M, Pankuweit S, Maisch B. Prognostic
significance of morphometric endomyocardial biopsy analysis
in patients with idiopathic dilated cardiomyopathy. 2003;146:
372-6
Grinfeld LR (see Berrocal et al). 2003;146:e22
Grom A (see Schmidt et al). 2003;146:908-13
Gross CP (see Krumholz et al). 2003;146:839-47
Gross CP (see Masoudi et al). 2003;146:250-7
Gruberg L (see Goldberg et al). 2003;146:819-23
Gu L (see Goff et al). 2003;146:1045-51
Guazzi M, De Vita S, Cardano P, Barlera S, Guazzi MD. Normaliza-
tion for peak oxygen uptake increases the prognostic power of
the ventilatory response to exercise in patients with chronic
heart failure. 2003;146:542-8
Guazzi MD (see Guazzi et al). 2003;146:542-8
Guida P (see De Tommasi et al). 2003;146:e17
Gupta R (see Gurm et al). 2003;146:692-8
Gurbel PA, Bliden KP. Platelet activation after stenting with hepa-
rin-coated versus noncoated stents. 2003;146:e10
Gurbel PA (see Serebruany et al). 2003;146:91-8
Gurm HS, Bhatt DL, Gupta R, Ellis SG, Topol EJ, Lauer MS. Prepro-
cedural white blood cell count and death after percutaneous
coronary intervention. 2003;146:692-8

H

- Haas SJ, Vos T, Gilbert RE, Krum H. Are β -blockers as efficacious in
patients with diabetes mellitus as in patients without diabetes
mellitus who have chronic heart failure? A meta-analysis of
large-scale clinical trials. 2003;146:848-53
Haas T (see Melenovsky et al). 2003;146:e1
Haim M (see Hasdai et al). 2003;146:832-8
Hall C (see Wijeyesundera et al). 2003;146:291-7
Halperin JL, SPORTIF Executive Steering Committee. Ximelagatran
compared with warfarin for prevention of thromboembolism in
patients with nonvalvular atrial fibrillation: rationale, objectives,
and design of a pair of clinical studies and baseline patient
characteristics (SPORTIF III and V). 2003;146:431-8 (Trial de-
sign)
Halperin JL (see Gomberg-Maitland et al). 2003;146:398-403 (Cur-
riculum cardi-ol.)
Halpern SD, Karlawish JHT, Casarett D, Berlin JA, Townsend RR,
Asch DA. Hypertensive patients' willingness to participate in
placebo-controlled trials: implications for recruitment effi-
ciency. 2003;146:985-92 (Trial design)
Haluska BA, Short L, Marwick TH. Relationship of ventricular lon-
gitudinal function to contractile reserve in patients with mitral
regurgitation. 2003;146:183-8
Hambrecht R (see Erbs et al). 2003;146:280-5
Hambrecht R (see Sick et al). 2003;146:134-41
Hammar N (see Kim et al). 2003;146:555-60
Hammer DF (see Schwartzman et al). 2003;146:535-41
Hammill B (see Allen LaPointe et al). 2003;146:894-901
Hammill SC (see Hedén et al). 2003;146:797-803 (Curriculum car-
diol.)

- Hansen MS (see Wijeyesundera et al). 2003;146:291-7
- Hanson MW (see Jiang et al). 2003;146:55-61
- Harrington RA (see Fergusson et al). 2003;146:628-34
- Harrington RA (see Roe et al). 2003;146:605-12 (Progress cardiol.)
- Harrison JK (see Krasuski et al). 2003;146:1099-104
- Hart NI (see Carlquist et al). 2003;146:1007-14
- Hasdai D, Haim M, Behar S, Boyko V, Battler A. Acute coronary syndromes in patients with prior cerebrovascular events: lessons from the Euro-Heart Survey of Acute Coronary Syndromes. 2003;146:832-8
- Hasselblad V (see Bourque et al). 2003;146:621-7
- Hauser ER, Allen AS. Where the rubber meets the road in pharmacogenetics: assessment of gene-environment interactions. 2003;146:929-31 (Editorial)
- Hausleiter J, Kastrati A, Mehilli J, Schühlen H, Pache J, Dotzer F, Sattelberger U, Dirschinger J, Schömig A. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STERO trial. 2003;146:882-6
- Havranek EP (see Masoudi et al). 2003;146:250-7
- Hayashi T (see Iwai et al). 2003;146:106-9
- Heart and Estrogen/progestin Replacement Study (HERS) Investigators (see Shlipak et al). 2003;146:870-5
- Hedén B, Ripa R, Persson E, Song Q, Maynard C, Leibrandt P, Wall T, Christian TF, Hammill SC, Bell SS, Pahlm O, Wagner GS. A modified Anderson-Wilkins electrocardiographic acuteness score for anterior or inferior myocardial infarction. 2003;146:797-803 (Curriculum cardiol.)
- Hedman A (see Alam et al). 2003;146:520-6
- Hee T (see Shen et al). 2003;146:741-5
- Hellkamp A (see Flaker et al). 2003;146:887-93
- Helms R (see Herrington et al). 2003;146:662-7
- Hennekens CH (see Meir et al). 2003;146:199-202 (Editorial)
- Hentschel B (see Sick et al). 2003;146:134-41
- Herd JA, Hoogwerf BJ, Barton F, Terrin ML, Czajkowski SM, Lindquist R, Dupuis G. Heart rate and blood pressure responses to mental stress and clinical cardiovascular events in men and women after coronary artery bypass grafting: the Post Coronary Artery Bypass Graft (Post-CABG) biobehavioral study. 2003;146:273-9
- Herd JA (see Lindquist et al). 2003;146:1038-44
- Herlitz J, McGovern P, Dellborg M, Karlsson T, Duval S, Karlson BW, Lee S, Luepker RV. Comparison of treatment and outcomes for patients with acute myocardial infarction in Minneapolis/St. Paul, Minnesota, and Göteborg, Sweden. 2003;146:1023-9
- Herlitz J (see Jánosi et al). 2003;146:721-8
- Hernandez AF (see Petersen et al). 2003;146:19-26 (Meetings)
- Hernández-Antolín R (see Moreno et al). 2003;146:e6 (Letter)
- Hernandez-Bernal F (see Latini et al). 2003;146:e2
- Herrington DM, Kessler K, Reiber JHC, Davis W, Brown WV, Helms R, Mallon SM, Raines J. Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease. 2003;146:662-7
- Hertzberger DP (see Lamfers et al). 2003;146:479-83
- Herzog CA (see Best et al). 2003;146:345-50
- Hetmanski JB (see Ding et al). 2003;146:459-64
- Higano S (see Murtagh et al). 2003;146:99-105
- Higano ST (see Prasad et al). 2003;146:549-54
- Hilleman DE (see Oldemeyer et al). 2003;146:e23
- Hilton GJD (see Ziakas et al). 2003;146:699-704
- Hishida E (see Kinjo et al). 2003;146:324-30
- Hjalmarson Å (see Jánosi et al). 2003;146:721-8
- Hochman JS (see French et al). 2003;146:804-10
- Hochman JS (see Sadanandan et al). 2003;146:653-61
- Hoekstra JW (see Roe et al). 2003;146:993-8
- Hoepfner C (see Piegas et al). 2003;146:331-8
- Hokamaki J (see Miyamoto et al). 2003;146:465-71
- Hoke L (see Cohn et al). 2003;146:679-85
- Holland AE (see Kopecky et al). 2003;146:146-52
- Holmberg MJ (see Shen et al). 2003;146:741-5
- Holmes DR Jr (see Best et al). 2003;146:345-50
- Holmes DR Jr (see Cohen et al). 2003;146:513-19
- Holmes DR Jr (see Murtagh et al). 2003;146:99-105
- Holmes DR Jr (see Prasad et al). 2003;146:549-54
- Holmvang L (see Jurlander et al). 2003;146:757-63 (Progress cardiol.)
- Holubkov R (see Cohen et al). 2003;146:513-19
- Hoogeveen RC (see Ballantyne and Hoogeveen). 2003;146:227-33 (Progress cardiol.)
- Hooghoudt TEH (see Lamfers et al). 2003;146:479-83
- Hoogwerf B (see Lindquist et al). 2003;146:1038-44
- Hoogwerf BJ (see Herd et al). 2003;146:273-9
- Hopton LA (see Goldberg et al). 2003;146:705-12
- Hordacre A-L (see Cheok et al). 2003;146:978-84 (Trial design)
- Hori M (see Kinjo et al). 2003;146:324-30
- Horne BD (see Carlquist et al). 2003;146:1007-14
- Horne BD (see Muhlestein et al). 2003;146:351-8
- Horowitz JD (see Beltrame et al). 2003;146:84-90, e3 (Letter)
- Howard BV (see Devereux et al). 2003;146:527-34
- Howard BV (see Hsia et al). 2003;146:439-45
- Hradec J (see Melnikov et al). 2003;146:e1
- Hranitzky PM (see Petersen et al). 2003;146:19-26 (Meetings)
- Hsia J, Bittner V, Tripputi M, Howard BV. Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial. 2003;146:439-45
- Huang CF (see Liang et al). 2003;146:367-71
- Huang SC (see Liang et al). 2003;146:367-71
- Hulley SB (see Shlipak et al). 2003;146:870-5
- Hulot JS (see Isnard et al). 2003;146:729-35
- Hummel C (see Schmidt et al). 2003;146:908-13
- Hunninghake DB (see Ballantyne et al). 2003;146:862-9
- Hunninghake DB (see Lindquist et al). 2003;146:1038-44
- Hustad CM (see Ballantyne et al). 2003;146:862-9
- Huynh T, Theroux P, Snapinn S, Wan Y. PRISM-PLUS Investigators. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). 2003;146:668-73
- Iacoviello M (see De Tommasi et al). 2003;146:e17
- Ibuki M (see Takagi et al). 2003;146:e5
- IEPR Investigators (see Linnemier et al). 2003;146:453-8
- Inoue I (see Ishihara et al). 2003;146:674-8
- Intermountain Heart Collaborative Study (IHCS) Group (see Muhlestein et al). 2003;146:351-8
- Inverso SM (see Spinler et al). 2003;146:33-41
- Ishihara H (see Umeda et al). 2003;146:75-83
- Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, Umemura T, Nakamura S, Yoshida M. Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction. 2003;146:674-8
- Isnard R, Pousset F, Chafirovskaja O, Carayon A, Hulot JS, Thomas D, Komajda M. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. 2003;146:729-35
- Isobe S (see Umeda et al). 2003;146:75-83
- Ivert T (see Kim et al). 2003;146:555-60
- Iwai C, Akita H, Kanazawa K, Shiga N, Terashima M, Matsuda Y, Takai E, Miyamoto Y, Shimizu M, Kajiya T, Hayashi T, Yokoyama M. Arg389Gly polymorphism of the human β 1-adrenergic receptor in patients with nonfatal acute myocardial infarction. 2003;146:106-9
- Iwase M (see Umeda et al). 2003;146:75-83
- Izawa H (see Umeda et al). 2003;146:75-83

J

- Jaarsma W (see De Boeck et al). 2003;146:411-19 (Progress cardiol.)
Jackson E (see Crowley et al). 2003;146:824-31
Jahangir A, Shen WK. Pacing in elderly patients. 2003;146:750-3 (Editorial)
Jain A (see Kopecky et al). 2003;146:146-52
Jakobsson K (see Kim et al). 2003;146:555-60
Jánosi A, Ghali JK, Herlitz J, Czurgai I, Klibaner M, Wikstrand J, Hjalmarson A, MERIT-HF Study Group. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. 2003;146:721-8
Januzzi JL, Cannon CP, Theroux P, Boden WE. Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention. 2003;146:764-74 (Curriculum cardiol.)
Jaski BE (see Goldberg et al). 2003;146:705-12
JELIS Investigators (see Yokoyama et al). 2003;146:613-20 (Trial design)
Jerome SD (see Serebruany et al). 2003;146:713-20
Jesse RL (see Kontos et al). 2003;146:446-52
Jiang S (see Chang et al). 2003;146:1112-14
Jiang W, Babyak MA, Rozanski A, Sherwood A, O'Connor CM, Waugh RA, Coleman RE, Hanson MW, Morris JJ, Blumenthal JA. Depression and increased myocardial ischemic activity in patients with ischemic heart disease. 2003;146:55-61
Johanson P (see Jurlander et al). 2003;146:757-63 (Progress cardiol.)
John B (see Chugh et al). 2003;146:635-9
John RM (see Meier-Ewert et al). 2003;146:339-44
Johnson MR (see Feinglass et al). 2003;146:111-14
Johnston JM (see Cohen et al). 2003;146:513-19
Jorgensen MB (see Kojoglanian et al). 2003;146:1077-81
Joseph L (see Pilote et al). 2003;146:1030-7
Jurlander B, Holmvang L, Galatius S, Vaught C, Johanson P, Krucoff MW, Grande P, Clemmensen P, Wagner GS. "Mirror-lake" serial relationship of electrocardiographic and biochemical indices for the detection of reperfusion and the prediction of salvage in patients with acute myocardial infarction. 2003;146:757-63 (Progress cardiol.)

K

- Kajiwara I (see Miyamoto et al). 2003;146:465-71
Kajiya T (see Iwai et al). 2003;146:106-9
Kanazawa K (see Iwai et al). 2003;146:106-9
Karas RH (see Kuvini et al). 2003;146:168-74
Karas RH (see Pourati et al). 2003;146:876-81
Karlawish JHT (see Halpern et al). 2003;146:985-92 (Trial design)
Karlson BW (see Herlitz et al). 2003;146:1023-9
Karlsson T (see Herlitz et al). 2003;146:1023-9
Kaski JC (see Smith et al). 2003;146:69-74
Kasper JM (see Engblom et al). 2003;146:359-66
Kasper JM (see Schwartzman et al). 2003;146:535-41
Kastrati A (see Böttiger et al). 2003;146:855-61
Kastrati A (see Hausleiter et al). 2003;146:882-6
Katan MB (see Geelen et al). 2003;146:e4
Katayama M (see Takagi et al). 2003;146:e5
Katsouras CS (see Michalis et al). 2003;146:304-10
Kaul UA (see Tyagi et al). 2003;146:920-8
Kawagoe T (see Ishihara et al). 2003;146:674-8
Kay JE (see Krasuski et al). 2003;146:1099-104
Keal RP (see Sensky et al). 2003;146:e13
Keebler ME, McGuire DK. Subclinical diabetes mellitus: is it really "sub-clinical"? 2003;146:210-12 (Editorial)
Kellett M (see Kopecky et al). 2003;146:146-52
Kelsey SF (see Cohen et al). 2003;146:513-19
Kennard ED (see Linnemeier et al). 2003;146:453-8
Kent K (see Leborgne et al). 2003;146:501-6
Kent KM (see Cheneau et al). 2003;146:142-5

- Kereiakes DJ. Inflammation as a therapeutic target: a unique role for abciximab. 2003;146:S1-4
Kerngord S (see Murphy et al). 2003;146:42-7
Kernzner R, Gage BF, Freedland KE, Rich MW. Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction. 2003;146:286-90
Kesler K (see Herrington et al). 2003;146:662-7
Khan IA (see Gowda et al). 2003;146:404-10 (Curriculum cardiol.)
Al-Khatib SM, Biswas MS. Patients' willingness to participate in placebo-controlled trials of antihypertensive therapy. 2003;146:944-5 (Editorial)
Kim J, Hammar N, Jakobsson K, Luepker RV, McGovern PG, Ivert T. Obesity and the risk of early and late mortality after coronary artery bypass graft surgery. 2003;146:555-60
Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. 2003;146:948-57 (Curriculum cardiol.)
Kim Y-J (see Shin et al). 2003;146:914-19
Kimber SKM (see Vollmann et al). 2003;146:1066-70
Kimmelstiel C (see Pourati et al). 2003;146:876-81
Kinjo K, Sato H, Sato H, Ohnishi Y, Hishida E, Nakatani D, Mizuno H, Ohgita N, Kubo M, Shimazu T, Akehi N, Takeda H, Hori M, Osaka Acute Coronary Insufficiency Study (OACIS) Group. Joint effects of *Chlamydia pneumoniae* infection and classic coronary risk factors on risk of acute myocardial infarction. 2003;146:324-30
Kinloch FRD (see Ziakas et al). 2003;146:699-704
Kip KE (see Cohen et al). 2003;146:513-19
Kisslo KB (see Krasuski et al). 2003;146:1099-104
Klepper RL (see Deutschman et al). 2003;146:62-8
Klibaner M (see Jánosi et al). 2003;146:721-8
Klinke BP (see Ziakas et al). 2003;146:699-704
Knatterud GL (see Lindquist et al). 2003;146:1038-44
Knopp RH (see Shlipak et al). 2003;146:870-5
Ko SF (see Liang et al). 2003;146:367-71
Kobayashi T (see Takeda et al). 2003;146:175-82
Kobayashi T (see Takeda et al). 2003;146:175-82
Kobayashi Y (see Takeda et al). 2003;146:175-82
Koch W (see Böttiger et al). 2003;146:855-61
Kojima S (see Miyamoto et al). 2003;146:465-71
Kojoglanian SA, Jorgensen MB, Wolde-Tsadiq G, Burchette RJ, Aharonian VJ. Restenosis in Intervened Coronaries with Hyperhomocysteinemia (RICH). 2003;146:1077-81
Kolodziej A (see Sadanandan et al). 2003;146:653-61
Komajda M (see Isnard et al). 2003;146:729-35
Kondo J, Sone T, Tsuboi H, Mukawa H, Morishima I, Uesugi M, Kono T, Kosaka T, Yoshida T, Numaguchi Y, Matsui H, Murohara T, Okumura K. Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. 2003;146:e20
Kono T (see Kondo et al). 2003;146:e20
Konstam MA. Matters of the heart: assessing the cardiovascular safety of new drugs. 2003;146:561-2 (Editorial)
Kontos MC, Fritz LM, Anderson FP, Tatum JL, Ornato JP, Jesse RL. Impact of the troponin standard on the prevalence of acute myocardial infarction. 2003;146:446-52
Kopecky SL, Aviles RJ, Bell MR, Lobl JK, Tipping D, Frommelt G, Ramsey K, Holland AE, Midei M, Jain A, Kellett M, Gibbons RJ. A randomized, double-blind, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction Reduction) study. 2003;146:146-52
Kopecky SL (see Brilakis et al). 2003;146:811-18
Kopecky SL (see Tedesco et al). 2003;146:472-8
Kosaka T (see Kondo et al). 2003;146:e20
Kozich V (see Melenovsky et al). 2003;146:e1

- Kramer JM (see Allen LaPointe et al). 2003;146:894-901
- Krasuski RA, Bush A, Kay JE, Mayes CE Jr, Wang A, Fleming J, Pierce C, Kisslo KB, Harrison JK, Bashore TM. C-reactive protein elevation independently influences the procedural success of percutaneous balloon mitral valve commissurotomy. 2003;146:1099-104
- Krasuski RA (see Shry et al). 2003;146:1090-4
- Kraus WE (see Cobb et al). 2003;146:572-80 (Editorial)
- Krijt J (see Melenovsky et al). 2003;146:e1
- Krucoff MW (see Jurlander et al). 2003;146:757-63 (Progress cardi.)
- Krum H (see Haas et al). 2003;146:848-53
- Krumholz HM, Chen J, Rathore SS, Wang Y, Radford MJ. Regional variation in the treatment and outcomes of myocardial infarction: investigating New England's advantage. 2003;146:242-9
- Krumholz HM, Gross CP, Peterson ED, Barron HV, Radford MJ, Parsons LS, Every NR. Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-I study. 2003;146:839-47
- Krumholz HM (see Masoudi et al). 2003;146:250-7
- Kubo M (see Kinjo et al). 2003;146:324-30
- Kurisu S (see Ishihara et al). 2003;146:674-8
- Kavin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, Karas RH, Udelson JE. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. 2003;146:168-74
- Kwan J (see Shin et al). 2003;146:914-19
- L**
- La Rovere MT (see De Caterina et al). 2003;146:420-30 (Progress cardi.)
- Labarta V (see Latini et al). 2003;146:e2
- Lahn C (see Böttiger et al). 2003;146:855-61
- Lakkis N (see Chang et al). 2003;146:1112-14
- Lamas G (see Flaker et al). 2003;146:887-93
- Lammers EJP, Schut A, Hooghoudt TEH, Hertzberger DP, Boersma E, Simoons ML, Verheugt FWA. Prehospital thrombolysis with reteplase: the Nijmegen/Rotterdam study. 2003;146:479-83
- Lampe F (see Müller et al). 2003;146:1061-5
- Langer A (see Sinnaeve et al). 2003;146:27-32
- Langhorst J (see Michalsen et al). 2003;146:e11
- Latini R, Staszewsky L, Maggioni AP, Marino P, Hernandez-Bernal F, Tognoni G, Labarta V, Gramenzi S, Bianchi F, Sarcina G, Cremonesi G, Nicolosi GL, Geraci E, Delapril Remodeling after Acute Myocardial Infarction (DRAM) Collaborative Group. Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAM) trial. 2003;146:e2
- Lauer B (see Sick et al). 2003;146:134-41
- Lauer MS (see Baker et al). 2003;146:736-40
- Lauer MS (see Gurm et al). 2003;146:692-8
- Lavasani F (see Muhlestein et al). 2003;146:351-8
- Lavecchia R (see Di Lenarda et al). 2003;146:e12
- Leborgne L, Cheneau E, Pichard A, Ajani A, Pakala R, Yazdi H, Satler L, Kent K, Suddath WO, Pinnow E, Canos D, Waksman R. Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. 2003;146:501-6
- Leborgne L (see Cheneau et al). 2003;146:142-5
- Lee CR, Watkins ML, Patterson JH, Gattis W, O'Connor CM, Gheorghiadu M, Adams KF Jr. Vasopressin: a new target for the treatment of heart failure. 2003;146:9-18 (Progress cardi.)
- Lee ET (see Devereux et al). 2003;146:527-34
- Lee K (see Flaker et al). 2003;146:887-93
- Lee S (see Herlitz et al). 2003;146:1023-9
- Leibrandt P (see Hedén et al). 2003;146:797-803 (Curriculum cardi.)
- Leitersdorf E (see Meir et al). 2003;146:199-202 (Editorial)
- Lennon R (see Best et al). 2003;146:345-50
- Lennon R (see Murtagh et al). 2003;146:99-105
- Lennon RJ (see Prasad et al). 2003;146:549-54
- Leon MB, Bakhai A. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future. 2003;146:S13-17
- Lerman A (see Murtagh et al). 2003;146:99-105
- Lerman A (see Prasad et al). 2003;146:549-54
- Leslie S (see Beltrame et al). 2003;146:e3 (Letter)
- Lessard D (see Crowley et al). 2003;146:824-31
- Li H (see Shen et al). 2003;146:741-5
- Liang CD, Ko SF, Huang SC, Huang CF, Niu CK. Vocal cord paralysis after transcatheter coil embolization of patent ductus arteriosus. 2003;146:367-71
- Lima JA (see Nasir et al). 2003;146:969-77 (Progress cardi.)
- Limaye SB (see Beltrame et al). 2003;146:84-90
- Lin E (see Feinglass et al). 2003;146:111-14
- Lin F (see Shlipak et al). 2003;146:870-5
- Lincoff AM. Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where? 2003;146:S23-30
- Lindquist R, Dupuis G, Terrin ML, Hoogwerf B, Czajkowski S, Herd JA, Barton FB, Tracy MF, Hunninghake DB, Treat-Jacobson D, Shumaker S, Zyzanski S, Goldenberg I, Knatterud GL, POST CABG Biobehavioral Study Investigators. Comparison of health-related quality-of-life outcomes of men and women after coronary artery bypass surgery through 1 year: findings from the POST CABG Biobehavioral Study. 2003;146:1038-44
- Lindquist R (see Herd et al). 2003;146:273-9
- Linke A (see Erbs et al). 2003;146:280-5
- Linnemeier G, Rutter MK, Barsness G, Kennard ED, Nesto RW, IEPRI Investigators. Enhanced External Counterpulsation for the relief of angina in patients with diabetes: safety, efficacy and 1-year clinical outcomes. 2003;146:453-8
- Lischinsky S (see Goldberg et al). 2003;146:819-23
- Liu JE (see Devereux et al). 2003;146:527-34
- Llorca J (see Berrazuela et al). 2003;146:e14
- Lobl JK (see Kopecky et al). 2003;146:146-52
- Lockwood E, Fu Y, Wong B, Van de Werf F, Granger CB, Armstrong PW, Goodman SG, ASSENT-2 Investigators. Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. 2003;146:640-5
- Loh E (see Goldberg et al). 2003;146:705-12
- Lopaschuk GD (see Fragasso et al). 2003;146:e18
- López J (see Rollán et al). 2003;146:1095-8
- Loubani M (see Sensky et al). 2003;146:e13
- Lowry DR (see Serebruany et al). 2003;146:713-20
- Lu B (see Yamamoto et al). 2003;146:153-9
- Lucci D (see Di Lenarda et al). 2003;146:e12
- Lüdtke R (see Michalsen et al). 2003;146:e11
- Luepker RV (see Herlitz et al). 2003;146:1023-9
- Luepker RV (see Kim et al). 2003;146:555-60
- M**
- Macaya C (see Moreno et al). 2003;146:e6 (Letter)
- Machnig T (see Zeymer et al). 2003;146:686-91
- Madonna R (see De Caterina et al). 2003;146:420-30 (Progress cardi.)
- Magelli C (see Grigioni et al). 2003;146:298-303
- Maggioni AP (see Di Lenarda et al). 2003;146:e12
- Maggioni AP (see Latini et al). 2003;146:e2
- Magnani G (see Grigioni et al). 2003;146:298-303
- Magni JM (see Berrocal et al). 2003;146:e22
- Mahaffey KW (see Waters et al). 2003;146:958-68 (Curriculum cardi.)
- Mahesh M (see Nasir et al). 2003;146:969-77 (Progress cardi.)
- Mahley RW (see Bersot et al). 2003;146:1052-60
- Maisch B (see Grimm et al). 2003;146:372-6
- Malbohan I (see Stulc et al). 2003;146:e21

- Malik J (see Stulc et al). 2003;146:e21
- Malik J (see Melenovsky et al). 2003;146:e1
- Malinin AI (see Serebruany et al). 2003;146:91-8, 713-20
- Mallemla S (see Dunlap et al). 2003;146:265-72
- Mallon SM (see Herrington et al). 2003;146:662-7
- Mancini DM (see Goldberg et al). 2003;146:705-12
- Mao SS (see Yamamoto et al). 2003;146:153-9
- Marcello SR (see Connolly et al). 2003;146:489-93
- Margonato A (see Fragasso et al). 2003;146:e18
- Mariani M (see Smith et al). 2003;146:69-74
- Marino P (see Latini et al). 2003;146:e2
- Marker J (see Cheok et al). 2003;146:978-84 (Trial design)
- Markiewicz W (see Goldberg et al). 2003;146:819-23
- Márquez MF, Pastelin G. Hiccup as an electrocardiographic artifact simulating arrhythmias. 2003;146:e16 (Letter reply)
- Martin GJ (see Feinglass et al). 2003;146:111-14
- Marwick TH (see Haluska et al). 2003;146:183-8
- Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, Ordín DL, Krumholz HM. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. 2003;146:250-7
- Massari F (see De Tommasi et al). 2003;146:e17
- Massberg S, Mueller I, Besta F, Thomas P, Gawaz M. Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting. 2003;146:e19
- Massie BM (see Ansari and Massie). 2003;146:1-4 (Editorial)
- Massie BM (see Ansari et al). 2003;146:115-20
- Matas CAR (see Berrocal et al). 2003;146:e22
- Mathew V (see Murtagh et al). 2003;146:99-105
- Mathew V (see Prasad et al). 2003;146:549-54
- Mathieu G (see Di Lenarda et al). 2003;146:e12
- Matsuda Y (see Iwai et al). 2003;146:106-9
- Matsui H (see Kondo et al). 2003;146:e20
- Mavroggiorgos NC (see Brilakis et al). 2003;146:811-18
- Mayes CE Jr (see Krasuski et al). 2003;146:1099-104
- Maynard C (see Engblom et al). 2003;146:359-66
- Maynard C (see Hedén et al). 2003;146:797-803 (Curriculum cardiol.)
- Mazurek T (see Budaj et al). 2003;146:999-1006
- McCarthy PM (see Schwartzman et al). 2003;146:535-41
- McCormick D (see Arjomand et al). 2003;146:787-96 (Curriculum cardiol.)
- McDonnell MB (see Mozaffarian et al). 2003;146:1015-22
- McGovern P (see Herlitz et al). 2003;146:1023-9
- McGovern PG (see Kim et al). 2003;146:555-60
- McGowan JH, Cleland JGF. Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods. 2003;146:388-97 (Curriculum cardiol.)
- McGuire DK (see Keebler and McGuire). 2003;146:210-12 (Editorial)
- McMurdo MET (see Witham and McMurdo). 2003;146:e7 (Letter)
- McNamara RL (see Ding et al). 2003;146:459-64
- Meerkin D (see Sheppard et al). 2003;146:775-86 (Curriculum cardiol.)
- Mehilli J (see Böttiger et al). 2003;146:855-61
- Mehilli J (see Hausleiter et al). 2003;146:882-6
- Mehra MR (see Ventura and Mehra). 2003;146:215-17 (Editorial)
- Mehra NJ (see Gowda et al). 2003;146:404-10 (Curriculum cardiol.)
- Meier-Ewert HK, Gray M-E, John RM. Endocardial pacemaker or defibrillator leads with infected vegetations: a single-center experience and consequences of transvenous extraction. 2003;146:339-44
- Meir K, Leitersdorf E, Hennekens CH. Inflammation in atherosclerosis: causal or casual? The need for randomized trials. 2003;146:199-202 (Editorial)
- Melenovsky V, Stulc T, Kozich V, Grauova B, Krijt J, Wichterle D, Haas T, Malik J, Hradec J, Ceska R. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. 2003;146:e1
- Menon V (see Crowley et al). 2003;146:824-31
- MERIT-HF Study Group (see János et al). 2003;146:721-8
- Messerli FH. Of millimeterology and cannibalism: comparative antihypertensive efficacy of angiotensin receptor blockers. 2003;146:568-9 (Editorial)
- Meyers S (see Ricciardi et al). 2003;146:507-12
- Michaelides AP, Andrikopoulos GK, Oikonomou EV, Psomadaki ZD, Richter DJ, Dilaveris PE, Exadaktylos NI, Stefanadis CI, Toutouzas PK. Improved myocardial performance during repetitive exercise testing: the role of extracellular superoxide dismutase activity in a model of exercise-induced myocardial preconditioning. 2003;146:160-7
- Michalis LK, Katsouras CS, Papamichael N, Adamides K, Naka KK, Goudevenos J, Sideris DA. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. 2003;146:304-10
- Michalsen A, Lütke R, Bühring M, Spahn G, Langhorst J, Dobos GJ. Thermal hydrotherapy improves quality of life and hemodynamic function in patients with chronic heart failure. 2003;146:e11
- Midei M (see Kopecky et al). 2003;146:146-52
- Mildenberger CR (see Ziakas et al). 2003;146:699-704
- Miller D (see French et al). 2003;146:804-10
- Miller WL (see Tedesco et al). 2003;146:472-8
- Mintz G (see Cheneau et al). 2003;146:142-5
- Mitchell ARJ, Spurrell PAR, Sulke N. Circadian variation of arrhythmia onset patterns in patients with persistent atrial fibrillation. 2003;146:902-7
- Miyamoto S, Sakamoto T, Soejima H, Shimomura H, Kajiura I, Kojima S, Hokamaki J, Sugiyama S, Yoshimura M, Ozaki Y, Nakamura H, Yodoi J, Ogawa H. Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction. 2003;146:465-71
- Miyamoto Y (see Iwai et al). 2003;146:106-9
- Mizoguchi S (see Takagi et al). 2003;146:e5
- Mizuno H (see Kinjo et al). 2003;146:324-30
- Möbius-Winkler S (see Erbs et al). 2003;146:280-5
- Mode Selection Trial (MOST) Investigators (see Flaker et al). 2003;146:887-93
- Mohiuddin SM (see Shen et al). 2003;146:741-5
- Molhoek PG (see Armstrong et al). 2003;146:484-8
- Molhuizen HOF (see Carlquist et al). 2003;146:1007-14
- Mollod M (see Roe et al). 2003;146:993-8
- Monti L (see Fragasso et al). 2003;146:e18
- Mooss AN (see Oldemeyer et al). 2003;146:e23
- Mooss AN (see Shen et al). 2003;146:741-5
- Moraes RS (see Behling et al). 2003;146:494-500
- Moreno R, Hernández-Antolin R, Alfonso F, Macaya C. Diabetes mellitus and acute myocardial infarction: more data supporting a poorer microvasculature reperfusion. 2003;146:e6 (Letter)
- Morgan AW (see Serebruany et al). 2003;146:713-20
- Morioka S (see Takagi et al). 2003;146:e5
- Morishima I (see Kondo et al). 2003;146:e20
- Morris JJ (see Jiang et al). 2003;146:55-61
- Morrow DA. New insight into clinical risk scores for patients with acute coronary syndromes. 2003;146:754-6 (Editorial)
- Morrow DA (see de Lemos and Morrow). 2003;146:747-9 (Editorial)
- Mortensen LS (see Andersen et al). 2003;146:234-41 (Trial design)
- Mozaffarian D, Bryson CL, Spertus JA, McDonnell MB, Fihn SD. Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease. 2003;146:1015-22
- Mueller I (see Massberg et al). 2003;146:e19
- Muhlestein JB, Anderson JL, Horne BD, Lavasani F, Allen Maycock CA, Bair TL, Pearson RR, Carlquist JF, Intermountain Heart Collaborative Study (IHCS) Group. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. 2003;146:351-8
- Muhlestein JB (see Carlquist et al). 2003;146:1007-14
- Mukawa H (see Kondo et al). 2003;146:e20
- Mukherjee D, Eagle KA. Improving quality of care in the real world: efficacy versus effectiveness? 2003;146:946-7 (Editorial)

- Mukherjee D, Topol EJ. Pharmaceutical advertising versus research spending: are profits more important than patients? 2003;146:563-4 (Editorial)
- Mukhopadhyay S (see Tyagi et al). 2003;146:920-8
- Müller D, Lampe F, Wegscheider K, Schultheiss H-P, Behrens S. Annual distribution of ventricular tachycardias and ventricular fibrillation. 2003;146:1061-5
- Murohara T (see Kondo et al). 2003;146:e20
- Murphy SA, Dauterman K, de Lemos JA, Kermgard S, Antman EM, Braunwald E, Gibson CM. Thrombolysis In Myocardial Infarction (TIMI) 14 Investigators. Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. 2003;146:42-7
- Murtagh B, Higano S, Lennon R, Mathew V, Holmes DR Jr, Lerman A. Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment. 2003;146:99-105
- Musuraca A (see Grigioni et al). 2003;146:298-303

N

- Nagai K (see Takagi et al). 2003;146:e5
- Nagata K (see Umeda et al). 2003;146:75-83
- Nagueh S (see Chang et al). 2003;146:1112-14
- Nair CK (see Gowda et al). 2003;146:404-10 (Curriculum cardiol.)
- Naka KK (see Michalis et al). 2003;146:304-10
- Nakagawa T (see Takeda et al). 2003;146:175-82
- Nakajima N (see Deutschman et al). 2003;146:62-8
- Nakamura H (see Miyamoto et al). 2003;146:465-71
- Nakamura S (see Ishihara et al). 2003;146:67-48
- Nakatani D (see Kinjo et al). 2003;146:324-30
- Nasir K, Budoff MJ, Post WS, Fishman EK, Mahesh M, Lima JA, Blumenthal RS. Electron beam CT versus helical CT scans for assessing coronary calcification: current utility and future directions. 2003;146:969-77 (Progress cardiol.)
- Nesto RW (see Linnemeier et al). 2003;146:453-8
- Neto JMR (see Piegas et al). 2003;146:331-8
- Neuhaus K-L (see Zeymer et al). 2003;146:686-91
- Ni H. Prevalence of self-reported heart failure among US adults: results from the 1999 National Health Interview Survey. 2003;146:121-8
- NICE-3 Investigators (see Ferguson et al). 2003;146:628-34
- Nicolosi GL (see Latini et al). 2003;146:e2
- Niebauer J (see Sick et al). 2003;146:134-41
- Nielsen TT (see Andersen et al). 2003;146:23-41 (Trial design)
- Nieto FJ (see Ding et al). 2003;146:459-64
- Nishioka K (see Ishihara et al). 2003;146:67-48
- Nishizawa T (see Umeda et al). 2003;146:75-83
- Niu CK (see Liang et al). 2003;146:367-71
- Nóbrega ACL (see Behling et al). 2003;146:494-500
- Noda A (see Umeda et al). 2003;146:75-83
- Nogareda G (see Berrocal et al). 2003;146:e22
- Nonokawa M (see Umeda et al). 2003;146:75-83
- Nordlander R (see Alam et al). 2003;146:520-6
- Numaguchi Y (see Kondo et al). 2003;146:e20

O

- Oberti P (see Berrocal et al). 2003;146:e22
- Obuchowski NA (see Schwartzman et al). 2003;146:535-41
- O'Connor CM (see Bourque et al). 2003;146:621-7
- O'Connor CM (see Jiang et al). 2003;146:55-61
- O'Connor CM (see Lee et al). 2003;146:9-18 (Progress cardiol.)
- O'Connor CM (see Serebruany et al). 2003;146:91-8, 713-20
- Ogawa H (see Miyamoto et al). 2003;146:465-71
- Oh JK (see De Boeck et al). 2003;146:411-19 (Progress cardiol.)
- Ohgiani N (see Kinjo et al). 2003;146:324-30
- Ohman EM (see Roe et al). 2003;146:605-12 (Progress cardiol.) 993-8

- Ohnishi Y (see Kinjo et al). 2003;146:324-30
- Oikonomou EV (see Michaelides et al). 2003;146:160-7
- Okumura K (see Kondo et al). 2003;146:e20
- Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. 2003;146:e23
- Oliveri R (see Berrocal et al). 2003;146:e22
- Olschewski M (see Schmidt et al). 2003;146:908-13
- Olympios CD (see Zairis et al). 2003;146:1082-9
- Opasich C (see Di Lenarda et al). 2003;146:e12
- Orav EJ (see Goldberg et al). 2003;146:705-12
- Ordin DL (see Masoudi et al). 2003;146:250-7
- Origasa H (see Yokoyama et al). 2003;146:613-20 (Trial design)
- Ornato JP (see Kontos et al). 2003;146:446-52
- Osaka Acute Coronary Insufficiency Study (OACIS) Group (see Kinjo et al). 2003;146:324-30
- Ozaki Y (see Miyamoto et al). 2003;146:465-71

P

- Pache J (see Hausleiter et al). 2003;146:882-6
- Page MT (see Deutschman et al). 2003;146:62-8
- Page RL (see Connolly et al). 2003;146:489-93
- Pahlm O (see Engblom et al). 2003;146:359-66
- Pahlm O (see Hedén et al). 2003;146:797-803 (Curriculum cardiol.)
- Pakala R (see Leborgne et al). 2003;146:501-6
- Pakola S (see Armstrong et al). 2003;146:484-8
- Pallosi A (see Fragasso et al). 2003;146:e18
- Palmeri ST (see French et al). 2003;146:804-10
- Palmieri V (see Devereux et al). 2003;146:527-34
- Palmisano J (see Ballantyne et al). 2003;146:862-9
- Pandian NG (see Kuvin et al). 2003;146:168-74
- Pang JL (see Ricciardi et al). 2003;146:507-12
- Pankuweit S (see Grimm et al). 2003;146:372-6
- Papadaki OA (see Zairis et al). 2003;146:1082-9
- Papamichael N (see Michalis et al). 2003;146:304-10
- Parsons LS (see Krumholz et al). 2003;146:839-47
- Pastelin G (see Márquez and Pastelin). 2003;146:e16 (Letter reply)
- Patel AR (see Kuvin et al). 2003;146:168-74
- Patel MR (see Alexander and Patel). 2003;146:570-1 (Editorial)
- Patterson JH (see Lee et al). 2003;146:9-18 (Progress cardiol.)
- Peacock WF (see Roe et al). 2003;146:993-8
- Pearson RR (see Muhlestein et al). 2003;146:351-8
- Pedersen F (see Andersen et al). 2003;146:23-41 (Trial design)
- Pehrsson K (see Sinnavee et al). 2003;146:27-32
- Penrod J (see Pilote et al). 2003;146:1030-7
- Pépin GM (see Bersot et al). 2003;146:1052-60
- Pepine CJ (see Ferguson et al). 2003;146:628-34
- Pereira JCR (see Piegas et al). 2003;146:331-8
- Persson E (see Hedén et al). 2003;146:797-803 (Curriculum cardiol.)
- Petersen JL, Dery J-P, Fischl MC, Hernandez AF, Hranitzky PM, Rao SV, Rebeiz AG, Singh KP. Highlights from the American College of Cardiology Annual Scientific Sessions 2003: March 28 to April 2, 2003. 2003;146:19-26 (Meetings)
- Peterson ED (see Krumholz et al). 2003;146:839-47
- Peterson ED (see Roe et al). 2003;146:605-12 (Progress cardiol.)
- Piatti PM (see Fragasso et al). 2003;146:e18
- Pichard A (see Leborgne et al). 2003;146:501-6
- Pichard AD (see Cheneau et al). 2003;146:142-5
- Piegas LS, Avezum A, Pereira JCR, Neto JMR, Hoepfner C, Farran JA, Ramos RF, Timmerman A, Esteves JP. AFIRMAR Study Investigators. Risk factors for myocardial infarction in Brazil. 2003;146:331-8
- Pierce C (see Krasuski et al). 2003;146:1099-104
- Piette JD (see Goldberg et al). 2003;146:705-12
- Pilote L, Joseph L, Bétille P, Penrod J. Universal health insurance coverage does not eliminate inequities in access to cardiac procedures after acute myocardial infarction. 2003;146:1030-7
- Pilote L (see Eschbag et al). 2003;146:581-90 (Curriculum cardiol.)

- Pinnow E (see Leborgne et al). 2003;146:501-6
Pitzalis MV (see De Tommasi et al). 2003;146:e17
Plomondon ME (see Beinart et al). 2003;146:646-52
Poehlman ET (see Savage et al). 2003;146:317-23
Pollack CV Jr (see Roe et al). 2003;146:605-12 (Progress cardiol.)
Porcu M (see Di Lenarda et al). 2003;146:e12
POST CABG Biobehavioral Study Investigators (see Lindquist et al). 2003;146:1038-44
Post WS (see Nasir et al). 2003;146:969-77 (Progress cardiol.)
Potena L (see Grigioni et al). 2003;146:298-303
Pouloupoulou CG (see Zairis et al). 2003;146:1082-9
Pourati I, Kimmelstiel C, Rand W, Karas RH. Statin use is associated with enhanced collateralization of severely diseased coronary arteries. 2003;146:876-81
Pousset F (see Isnard et al). 2003;146:729-35
PRAISE II Investigators (see Wijeysondera et al). 2003;146:291-7
Prasad A, Higano ST, Al Suwaidi J, Holmes DR Jr, Mathew V, Pumper G, Lennon RJ, Lerman A. Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction. 2003;146:549-54
Precone DF (see Durante Mangoni et al). 2003;146:311-16
PRISM-PLUS Investigators (see Huynh et al). 2003;146:668-73
Pritchett ELC (see Connolly et al). 2003;146:489-93
Psarogianni PK (see Zairis et al). 2003;146:1082-9
Psomadaki ZD (see Michaelides et al). 2003;146:160-7
Puccetti P (see Frigasso et al). 2003;146:e18
Pumper G (see Prasad et al). 2003;146:549-54

Q

- Qin JX (see Shin et al). 2003;146:914-19

R

- Radford MJ (see Krumholz et al). 2003;146:242-9, 839-47
Ragone E (see Durante Mangoni et al). 2003;146:311-16
Raines J (see Herrington et al). 2003;146:662-7
Ramos RF (see Piegas et al). 2003;146:331-8
Ramsey K (see Kopecky et al). 2003;146:146-52
Ramsey KE (see Ballantyne et al). 2003;146:862-9
Rand W (see Pourati et al). 2003;146:876-81
Rao SV (see Petersen et al). 2003;146:19-26 (Meetings)
Rathore SS (see Krumholz et al). 2003;146:242-9
Rathore SS (see Masoudi et al). 2003;146:250-7
Rebeiz AG (see Petersen et al). 2003;146:19-26 (Meetings)
Reeder GS (see Brilakis et al). 2003;146:811-18
Reeder GS (see Tedesco et al). 2003;146:472-8
Reiber JHC (see Herrington et al). 2003;146:662-7
Reicin A (see Weir et al). 2003;146:591-604 (Progress cardiol.)
Ribeiro JP (see Behling et al). 2003;146:494-500
Ricciardi MJ, Meyers S, Choi K, Pang JL, Goodreau L, Davidson CJ. Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events. 2003;146:507-12
Rich MW (see Kerzner et al). 2003;146:286-90
Richter DJ (see Michaelides et al). 2003;146:160-7
Rihal CS (see Best et al). 2003;146:345-50
Rihal CS (see Brilakis et al). 2003;146:811-18
Ripa R (see Hedén et al). 2003;146:797-803 (Curriculum cardiol.)
Rizzon P (see De Tommasi et al). 2003;146:e17
Rockson SG (see Fenster et al). 2003;146:218-26 (Curriculum cardiol.)
Rodeheffer RJ (see Devereux et al). 2003;146:527-34
Rodriguez LL (see Shin et al). 2003;146:914-19
Rodriguez R (see Goldberg et al). 2003;146:705-12
Roe MT, Christenson RH, Ohman EM, Bahr R, Fesmire FM, Storrow A, Mollod M, Peacock WF, Rosenblatt JA, Yang H, Fraulo ES, Hockstra JW, Gibler WB, EARLY Investigators, Emergency Medicine Cardiac Research and Education Group (EMCREG). A

- randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. 2003;146:993-8
Roe MT, Ohman EM, Pollack CV Jr, Peterson ED, Brindis RG, Harrington RA, Christenson RH, Smith SC Jr, Califf RM, Gibler WB. Changing the model of care for patients with acute coronary syndromes. 2003;146:605-12 (Progress cardiol.)
Roe MT (see Waters et al). 2003;146:958-68 (Curriculum cardiol.)
Roessler R (see Cohn et al). 2003;146:679-85
Rohde LE (see Behling et al). 2003;146:494-500
Rollán MJ, Román JAS, Vilacosta I, Sarriá C, López J, Acuña M, Bratos JL. Clinical profile of *Streptococcus agalactiae* native valve endocarditis. 2003;146:1095-8
Román JAS (see Rollán et al). 2003;146:1095-8
Roman MJ (see Devereux et al). 2003;146:527-34
Romito R (see De Tommasi et al). 2003;146:e17
Root M (see Cobb et al). 2003;146:572-80 (Editorial)
Rosenblatt JA (see Roe et al). 2003;146:993-8
Ross A (see Sadanandan et al). 2003;146:653-61
Rouleau JL (see Wijeysondera et al). 2003;146:291-7
Rovang K (see Shen et al). 2003;146:741-5
Rozanski A (see Jiang et al). 2003;146:55-61
Rudolph S (see Grimm et al). 2003;146:372-6
Ruggiero G (see Durante Mangoni et al). 2003;146:311-16
Rumsfeld JS (see Beinart et al). 2003;146:646-52
Rutter MK (see Linnemeier et al). 2003;146:453-8

S

- Sabbadini RA (see Deutschman et al). 2003;146:62-8
Sacchi TJ (see Gowda et al). 2003;146:404-10 (Curriculum cardiol.)
Sadanandan S, Hochman JS, Kolodziej A, Criger DA, Ross A, Selvester R, Wagner GS. Clinical and angiographic characteristics of patients with combined anterior and inferior ST-segment elevation on the initial electrocardiogram during acute myocardial infarction. 2003;146:653-61
Sakamoto T (see Miyamoto et al). 2003;146:465-71
Sakurai M (see Takeda et al). 2003;146:175-82
Sales AE (see Beinart et al). 2003;146:646-52
Samad B (see Alam et al). 2003;146:520-6
Samani NJ (see Sensky et al). 2003;146:e13
Sampedro I (see Berrazuela et al). 2003;146:e14
Sanborn T (see French et al). 2003;146:804-10
Sanderson B (see Wu et al). 2003;146:129-33
Sane DC (see Serebruany et al). 2003;146:713-20
Sarcina G (see Latini et al). 2003;146:e2
Sarriá C (see Rollán et al). 2003;146:1095-8
Satler L (see Leborgne et al). 2003;146:501-6
Satler LF (see Cheneau et al). 2003;146:142-5
Sato H (see Kinjo et al). 2003;146:324-30
Sato H (see Kinjo et al). 2003;146:324-30
Sattelberger U (see Hausleiter et al). 2003;146:882-6
Savage PD, Brochu M, Pochman ET, Ades PA. Reduction in obesity and coronary risk factors after high caloric exercise training in overweight coronary patients. 2003;146:317-23
Scherillo M (see Di Lenarda et al). 2003;146:e12
Schiller NB. Ejection fraction by echocardiography: the full monty or just a peep show? 2003;146:380-2 (Editorial)
Schmidt B, Brunner M, Olschewski M, Hummel C, Faber TS, Grom A, Giesler U, Bode C, Zehender M. Pacemaker therapy in very elderly patients: long-term survival and prognostic parameters. 2003;146:908-13
Schnall RP (see Kuvín et al). 2003;146:168-74
Schneider B (see Stöllerberger et al). 2003;146:e26 (Letter)
Schneiderman N (see Watkins et al). 2003;146:48-54
Schnell DJ (see Connolly et al). 2003;146:489-93
Schömig A (see Böttiger et al). 2003;146:855-61
Schömig A (see Hausleiter et al). 2003;146:882-6
Schouten EG (see Geelen et al). 2003;146:e4
Schrader G (see Cheek et al). 2003;146:978-84 (Trial design)

- Schröder R (see Zeymer et al). 2003;146:686-91
- Schron E (see Flaker et al). 2003;146:887-93
- Schühlen H (see Hausleiter et al). 2003;146:882-6
- Schuler G (see Erbs et al). 2003;146:280-5
- Schuler G (see Sick et al). 2003;146:134-41
- Schultheiss H-P (see Müller et al). 2003;146:1061-5
- Schut A (see Lamfers et al). 2003;146:479-83
- Schwartzman PR, Srichai MB, Grimm RA, Obuchowski NA, Hammer DF, McCarthy PM, Kasper JM, White RD. Nonstress delayed-enhancement magnetic resonance imaging of the myocardium predicts improvement of function after revascularization for chronic ischemic heart disease with left ventricular dysfunction. 2003;146:535-41
- Schwartz TA (see Dunlap et al). 2003;146:265-72
- Sekandrazad MW (see Chang et al). 2003;146:1112-14
- Selvester R (see Sadanandan et al). 2003;146:653-61
- Selvester RH (see Engblom et al). 2003;146:359-66
- Selzer F (see Cohen et al). 2003;146:513-19
- Sensky PR, Loubani M, Keal RP, Samani NJ, Sosnowski AW, Galinanes M. Does the type of prosthesis influence early left ventricular mass regression after aortic valve replacement? Assessment with magnetic resonance imaging. 2003;146:e13
- Serebruany VL, Malinin AI, Jerome SD, Lowry DR, Morgan AW, Sane DC, Tanguay J-F, Steinhilb SR, O'Connor CM. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the PLavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. 2003;146:713-20
- Serebruany VL, Malinin AI, O'Connor CM, Gurbel PA. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). 2003;146:91-8
- Setola E (see Fragasso et al). 2003;146:e18
- Setser RM (see Engblom et al). 2003;146:359-66
- Shavelle D (see Yamamoto et al). 2003;146:153-9
- Sheedy DJ (see Goff et al). 2003;146:1045-51
- Sheffy J (see Kuvlin et al). 2003;146:168-74
- Shen WK (see Jahangir and Shen). 2003;146:750-3 (Editorial)
- Shen X, Li H, Rovang K, Hee T, Holmberg MJ, Mooss AN, Mohiuddin SM. Transesophageal echocardiography before cardioversion of recurrent atrial fibrillation: does absence of previous atrial thrombi preclude the need of a repeat test? 2003;146:741-5
- Sheppard R, Eisenberg MJ, Donath D, Meerkin D. Intracoronary brachytherapy for the prevention of restenosis after percutaneous coronary revascularization. 2003;146:775-86 (Curriculum cardiol.)
- Sheps DS, Bragdon EE. Are heart rate and blood pressure responses to mental stress predictive of clinical cardiovascular events? The answer varies by coronary artery disease syndrome. 2003;146:197-8 (Editorial)
- Sheps DS (see Watkins et al). 2003;146:48-54
- Sherwood A (see Jiang et al). 2003;146:55-61
- Shiga N (see Iwai et al). 2003;146:106-9
- Shimatani Y (see Ishihara et al). 2003;146:67-48
- Shimazu T (see Kinjo et al). 2003;146:324-30
- Shimizu M (see Iwai et al). 2003;146:106-9
- Shimomura H (see Miyamoto et al). 2003;146:465-71
- Shin J-H, Shiota T, Kim Y-J, Kwan J, Qin JX, Eto Y, Rodriguez LL, Thomas JD. False-positive exercise echocardiograms: impact of sex and blood pressure response. 2003;146:914-19
- Shiota T (see Shin et al). 2003;146:914-19
- Shiratori K (see Takagi et al). 2003;146:e5
- Shlipak MG, Chaput LA, Vittinghoff E, Lin F, Bittner V, Knopp RH, Hulley SB, Heart and Estrogen/progestin Replacement Study (HERS) Investigators. Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). 2003;146:870-5
- SHOCK Investigators (see French et al). 2003;146:804-10
- Short L (see Haluska et al). 2003;146:183-8
- Shry EA, Eckart RE, Furgerson JL, Stajduhar KC, Krasuski RA. Addition of right-sided and posterior precordial leads during stress testing. 2003;146:1090-4
- Shumaker S (see Lindquist et al). 2003;146:1038-44
- Sick PB, Thiele H, Brosteanu O, Hentschel B, Lauer B, Niebauer J, Hambrecht R, Schuler G. Prospective randomized comparison of early and late results of 4 different stent designs. 2003;146:134-41
- Sideris DA (see Michalis et al). 2003;146:304-10
- Simoons ML (see Lamfers et al). 2003;146:479-83
- Singh KP (see Petersen et al). 2003;146:19-26 (Meetings)
- Singh S (see Tyagi et al). 2003;146:920-8
- Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, Ardissino D, Vahanian A, Pehrsson K, Armstrong P, Van de Werf F, ASSENT-2 Investigators. One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. 2003;146:27-32
- Sleeper LA (see French et al). 2003;146:804-10
- Sliney KA (see Kuvlin et al). 2003;146:168-74
- Smith AL (see Goldberg et al). 2003;146:705-12
- Smith DA, Zouridakis EG, Mariani M, Fredericks S, Cole D, Kaski JC. Neopterin levels in patients with coronary artery disease are independent of *Chlamydia pneumoniae* seropositivity. 2003;146:69-74
- Smith SC Jr (see Roe et al). 2003;146:605-12 (Progress cardiol.)
- Smith WS (see Deutschman et al). 2003;146:62-8
- Snappin S (see Huynh et al). 2003;146:668-73
- Soejima H (see Miyamoto et al). 2003;146:465-71
- Sommers PA (see Cohn et al). 2003;146:679-85
- Sone T (see Kondo et al). 2003;146:e20
- Song Q (see Hedén et al). 2003;146:797-803 (Curriculum cardiol.)
- Sosnowski AW (see Sensky et al). 2003;146:e13
- Soukupová J (see Stulc et al). 2003;146:e21
- Spahn G (see Michalsen et al). 2003;146:e11
- Specchia S (see Grigioni et al). 2003;146:298-303
- Spencer W III (see Chang et al). 2003;146:1112-14
- Spertus JA (see Weir et al). 2003;146:591-604 (Progress cardiol.)
- Spertus JA (see Beinart et al). 2003;146:646-52
- Spertus JA (see Mozaffarian et al). 2003;146:1015-22
- Spinetta AD (see Berrocal et al). 2003;146:e22
- Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM, ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. 2003;146:33-41
- Spodick DH. Left bundle branch block is not equivalent to "absent septal q wave." 2003;146:e9 (Letter)
- SPORTIF Executive Steering Committee (see Halperin and SPORTIF Executive Steering Committee). 2003;146:431-8 (Trial design)
- Spurrell PAR (see Mitchell et al). 2003;146:902-7
- Srichai MB (see Schwartzman et al). 2003;146:535-41
- Stajduhar KC (see Shry et al). 2003;146:1090-4
- Stanton E (see Wijeysondera et al). 2003;146:291-7
- Staszewsky L (see Latini et al). 2003;146:e2
- Stefanadis CI (see Michaelides et al). 2003;146:160-7
- Steiner JF (see Masoudi et al). 2003;146:250-7
- Steingart R (see French et al). 2003;146:804-10
- Steinhilb SR. Percutaneous coronary interventions in patients with renal insufficiency: a high-risk, under-studied cohort. 2003;146:213-4 (Editorial)
- Steinhilb SR (see Serebruany et al). 2003;146:713-20
- Stewart WJ. Myocardial factor for timing of surgery in asymptomatic patients with mitral regurgitation. 2003;146:5-8 (Editorial)
- Stöllberger C, Schneider B, Finsterer J. Is left atrial appendage occlusion during routine coronary artery bypass graft surgery useful for stroke prevention? 2003;146:e26 (Letter)
- Storrow A (see Roe et al). 2003;146:993-8
- Stringer KA (see Spinler et al). 2003;146:33-41
- Stulc T (see Melenovsky et al). 2003;146:e1

- Stulc T, Malbohan I, Malík J, Fialová L, Soukupová J, Ceska R. Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. 2003;146:e21
Suddath WO (see Leborgne et al). 2003;146:501-6
Sueta CA. Heart rate variability in chronic heart failure: target for therapy? 2003;146:385-7 (Editorial)
Sueta CA (see Dunlap et al). 2003;146:265-72
Sugiyama S (see Miyamoto et al). 2003;146:465-71
Suissa S (see Essebag et al). 2003;146:581-90 (Curriculum cardiol.)
Sulke N (see Mitchell et al). 2003;146:902-7
Al Suwaidi J (see Prasad et al). 2003;146:549-54
Swenne CA (see Geelen et al). 2003;146:e4

T

- Taccardi AA (see Di Napoli et al). 2003;146:1105-11
Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. 2003;146:e5
Takai E (see Iwai et al). 2003;146:106-9
Takasu J (see Yamamoto et al). 2003;146:153-9
Takeda H (see Kinjo et al). 2003;146:324-30
Takeda Y, Tsuchikane E, Kobayashi T, Terai K, Kobayashi Y, Nakagawa T, Sakurai M, Awata N, Kobayashi T. Effect of plaque debulking before stent implantation on in-stent neointimal proliferation: a serial 3-dimensional intravascular ultrasound study. 2003;146:175-82
Tamita K (see Takagi et al). 2003;146:e5
Tanabe K (see Takagi et al). 2003;146:e5
Tanguay J-F (see Serebruany et al). 2003;146:713-20
Tani T (see Takagi et al). 2003;146:e5
Tardiff B (see Flaker et al). 2003;146:887-93
Tatum JL (see Kontos et al). 2003;146:446-52
Tavazzi L (see Di Lenarda et al). 2003;146:e12
Taylor AL (see Cohn et al). 2003;146:679-85
Taylor CB (see Watkins et al). 2003;146:48-54
Taylor HA Jr (see Ding et al). 2003;146:459-64
Tedesco JV, Williams BA, Wright RS, Reeder GS, Dvorak D, Kopecky SL, Miller WL. Coronary Care Unit Group. Baseline comorbidities and treatment strategy in elderly patients are associated with outcome of cardiogenic shock in a community-based population. 2003;146:472-8
TEMISTOCLE Investigators (see Di Lenarda et al). 2003;146:e12
Temple RJ. Choice of treatment: outcomes and treatment goals. 2003;146:565-7 (Editorial)
Tendera M (see Armstrong et al). 2003;146:484-8
Terai K (see Takeda et al). 2003;146:175-82
Terashima M (see Iwai et al). 2003;146:106-9
Terrin ML (see Herd et al). 2003;146:273-9
Terrin ML (see Lindquist et al). 2003;146:1038-44
Thayssen P (see Andersen et al). 2003;146:234-41 (Trial design)
Theroux P (see Ferguson et al). 2003;146:628-34
Theroux P (see Huynh et al). 2003;146:668-73
Theroux P (see Januzzi et al). 2003;146:764-74 (Curriculum cardiol.)
Thiele H (see Sick et al). 2003;146:134-41
Thoma MA (see Zairis et al). 2003;146:1082-9
Thomas C (see Baker et al). 2003;146:258-64
Thomas D (see Isnard et al). 2003;146:729-35
Thomas JD (see Shin et al). 2003;146:914-19
Thomas P (see Massberg et al). 2003;146:e19
Thrombolysis In Myocardial Infarction (TIMI) 14 Investigators (see Murphy et al). 2003;146:42-7
Timerman A (see Piegas et al). 2003;146:331-8
TIMI 11B Investigators (see Spinler et al). 2003;146:33-41
Ting HH (see Best et al). 2003;146:345-50

- Tipping D (see Kopecky et al). 2003;146:146-52
Titus JL (see Chugh et al). 2003;146:635-9
Tognoni G (see Latini et al). 2003;146:e2
Topol EJ (see Gurm et al). 2003;146:692-8
Topol EJ (see Mukherjee and Topol). 2003;146:563-4 (Editorial)
Toutouzas PK (see Michaelides et al). 2003;146:160-7
Townsend RR (see Halpern et al). 2003;146:985-92 (Trial design)
Tracy MF (see Lindquist et al). 2003;146:1038-44
Treat-Jacobson D (see Lindquist et al). 2003;146:1038-44
Trifunopoulou KG (see Zairis et al). 2003;146:1082-9
Tripodi M-F (see Durante Mangoni et al). 2003;146:311-16
Tripputi M (see Hsia et al). 2003;146:439-45
Tsao PS (see Fenster et al). 2003;146:218-26 (Curriculum cardiol.)
Tsuboi H (see Kondo et al). 2003;146:e20
Tsuchikane E (see Takeda et al). 2003;146:175-82
Turi ZG (see Arjormand et al). 2003;146:787-96 (Curriculum cardiol.)
Turner SP (see Beltrame et al). 2003;146:e3 (Letter)
Tutar A (see Ansari et al). 2003;146:115-20
Tyagi S, Singh S, Mukhopadhyay S, Kaul UA. Self- and balloon-expandable stent implantation for severe native coarctation of aorta in adults. 2003;146:920-8
Tyroler HA (see Ding et al). 2003;146:459-64

U

- Udelson JE (see Kuvin et al). 2003;146:168-74
Uesugi M (see Kondo et al). 2003;146:e20
Umeda H, Iwase M, Izawa H, Nishizawa T, Nonokawa M, Isobe S, Noda A, Nagata K, Ishihara H, Yokota M. Biphasic relaxation-frequency relations in patients with effort angina pectoris: a new marker of myocardial demand ischemia. 2003;146:75-83
Umehara T (see Ishihara et al). 2003;146:674-8
Unterberg C (see Vollmann et al). 2003;146:1066-70
Utili R (see Durante Mangoni et al). 2003;146:311-16

V

- Vaccarino V. Women and outcomes of coronary artery bypass surgery: do we have an answer? 2003;146:935-7 (Editorial)
Vahanian A (see Armstrong et al). 2003;146:484-8
Vahanian A (see Sinnaeve et al). 2003;146:27-32
Van de Werf F (see Armstrong et al). 2003;146:484-8
Van De Werf F (see Budaj et al). 2003;146:999-1006
Van de Werf F (see Lockwood et al). 2003;146:640-5
Van de Werf F (see Sinnaeve et al). 2003;146:27-32
van der Aa RPLM (see De Boeck et al). 2003;146:411-19 (Progress cardiol.)
Vasavada BC (see Gowda et al). 2003;146:404-10 (Curriculum cardiol.)
Vaught C (see Jurlander et al). 2003;146:757-63 (Progress cardiol.)
Velazquez EJ (see Bourque et al). 2003;146:621-7
Ventura HO, Mehra MR. Hippocrates and prognosis in heart failure: the challenge of static and dynamic measurements. 2003;146:215-17 (Editorial)
Verheugt FWA (see Lamfers et al). 2003;146:479-83
Vesterlund T (see Andersen et al). 2003;146:234-41 (Trial design)
Vilacosta I (see Rollán et al). 2003;146:1095-8
Vittinghoff E (see Shlipak et al). 2003;146:870-5
Vollmann D, Ahern T, Gerritse B, Canby RC, Zenker D, Binner L, Kimber SKM, Unterberg C, Worldwide Medtronic Model 6944 Investigators. Worldwide evaluation of a defibrillation lead with a small geometric electrode surface for high-impedance pacing. 2003;146:1066-70
von Beckerath N (see Böttiger et al). 2003;146:855-61
Von Schulz C (see Berrocal et al). 2003;146:e22
Vos T (see Haas et al). 2003;146:848-53

W

- Wagner GS (see Engblom et al). 2003;146:359-66
 Wagner GS (see Hedén et al). 2003;146:797-803 (Curriculum cardiol.)
 Wagner GS (see Jurlander et al). 2003;146:757-63 (Progress cardiol.)
 Wagner GS (see Sadanandan et al). 2003;146:653-61
 Waksman R (see Cheneau et al). 2003;146:142-5
 Waksman R (see Leborgne et al). 2003;146:501-6
 Wall T (see Hedén et al). 2003;146:797-803 (Curriculum cardiol.)
 Walsh MN (see Goldberg et al). 2003;146:705-12
 Wan Y (see Huynh et al). 2003;146:668-73
 Wang A (see Krasuski et al). 2003;146:1099-104
 Wang Y (see Krumholz et al). 2003;146:242-9
 Waters RE II, Mahaffey KW, Granger CB, Roe MT. Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. 2003;146:958-68 (Curriculum cardiol.)
 Watkins LL, Schneiderman N, Blumenthal JA, Sheps DS, Catellier D, Taylor CB, Freedland KE, ENRICHD Investigators. Cognitive and somatic symptoms of depression are associated with medical comorbidity in patients after acute myocardial infarction. 2003;146:48-54
 Watkins ML (see Lee et al). 2003;146:9-18 (Progress cardiol.)
 Waugh RA (see Jiang et al). 2003;146:55-61
 Wegscheider K (see Müller et al). 2003;146:1061-5
 Weintraub WS (see Brindis et al). 2003;146:932-4 (Editorial)
 Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. 2003;146:591-604 (Progress cardiol.)
 Weissman N (see Cheneau et al). 2003;146:142-5
 WHARF Investigators (see Goldberg et al). 2003;146:705-12
 White RD (see Engblom et al). 2003;146:359-66
 White RD (see Schwartzman et al). 2003;146:535-41
 Whitwam W (see Cohn et al). 2003;146:679-85
 Wichterle D (see Melenovsky et al). 2003;146:e1
 Wijeyesundera HC, Hansen MS, Stanton E, Cropp AS, Hall C, Dhalla NS, Ghali J, Rouleau JL, PRAISE II Investigators. Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. 2003;146:291-7
 Wikstrand J (see János et al). 2003;146:721-8
 Wilkinson WE (see Connolly et al). 2003;146:489-93
 Williams BA (see Brilakis et al). 2003;146:811-18
 Williams BA (see Tedesco et al). 2003;146:472-8
 Williams DO (see Cohen et al). 2003;146:513-19
 Williams EMB (see Ziakas et al). 2003;146:699-704
 Williams ES, Zipes DP. The winter's tale—and toll. 2003;146:941-3 (Editorial)
 Witham MD, McMurdo MET. Don't shoot the messenger: the 6-minute walk test is a useful outcome measure in exercise trials. 2003;146:e7 (Letter)
 Wolde-Tsadiq G (see Kojoglanian et al). 2003;146:1077-81
 Wolfe P (see Masoudi et al). 2003;146:250-7
 Wong B (see Lockwood et al). 2003;146:640-5
 Worldwide Medtronic Model 6944 Investigators (see Vollmann et al). 2003;146:1066-70
 Wright RS (see Brilakis et al). 2003;146:811-18
 Wright RS (see Tedesco et al). 2003;146:472-8

- Wu G, Sanderson B, Bittner V. The 6-minute walk test: how important is the learning effect? 2003;146:129-33
 Wu Z (see Cheneau et al). 2003;146:142-5
 Wurdeman RL (see Oldemeyer et al). 2003;146:e23
 Wuttke RD (see Beltrame et al). 2003;146:84-90

Y

- Yamabe K (see Takagi et al). 2003;146:e5
 Yamamoto H, Shavelle D, Takasu J, Lu B, Mao SS, Fischer H, Budoff MJ. Valvular and thoracic aortic calcium as a marker of the extent and severity of angiographic coronary artery disease. 2003;146:153-9
 Yamamoto A (see Takagi et al). 2003;146:e5
 Yancy CW. Does race matter in heart failure? 2003;146:203-6 (Editorial)
 Yang H (see Roe et al). 2003;146:993-8
 Yarzebski J (see Crowley et al). 2003;146:824-31
 Yazdi H (see Leborgne et al). 2003;146:501-6
 Yodoi J (see Miyamoto et al). 2003;146:465-71
 Yokota M (see Umeda et al). 2003;146:75-83
 Yokoyama M, Origasa H, JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). 2003;146:613-20 (Trial design)
 Yokoyama M (see Iwai et al). 2003;146:106-9
 Yoshida M (see Ishihara et al). 2003;146:674-8
 Yoshida T (see Kondo et al). 2003;146:e20
 Yoshikawa J (see Takagi et al). 2003;146:e5
 Yoshimura M (see Miyamoto et al). 2003;146:465-71
 Young TR (see Deutschman et al). 2003;146:62-8
 Yuan Z (see Ballantyne et al). 2003;146:862-9

Z

- Zairis MN, Papadaki OA, Psarogianni PK, Thoma MA, Andrikopoulos GK, Batika PC, Pouloupoulou CG, Trifinopoulou KG, Olympios CD, Foussas SG. Serologic markers of persistent *Cblamydia pneumoniae* infection and long-term prognosis after successful coronary stenting. 2003;146:1082-9
 Zannoli R (see Grigioni et al). 2003;146:298-303
 Zdoroviyak A (see Goldberg et al). 2003;146:819-23
 Zehender M (see Schmidt et al). 2003;146:908-13
 Zenker D (see Vollmann et al). 2003;146:1066-70
 Zeymer U, Schröder R, Machnig T, Neuhaus K-L. Primary percutaneous transluminal coronary angioplasty accelerates early myocardial reperfusion compared to thrombolytic therapy in patients with acute myocardial infarction. 2003;146:686-91
 Zheng Z-J (see Chugh et al). 2003;146:635-9
 Ziakas AA, Klink BP, Mildnerberger CR, Fretz DE, Williams EMB, Kinloch FRD, Hilton GJD. Safety of same-day-discharge radial percutaneous coronary intervention: a retrospective study. 2003;146:699-704
 Zinder O (see Goldberg et al). 2003;146:819-23
 Zipes DP (see Williams and Zipes). 2003;146:941-3 (Editorial)
 Zock PL (see Geelen et al). 2003;146:e4
 Zouridakis EG (see Smith et al). 2003;146:69-74
 Zucchi R (see De Caterina et al). 2003;146:420-30 (Progress cardiol.)
 Zyzanski S (see Lindquist et al). 2003;146:1038-44

Subject index*

A

Abciximab

- Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting (Massberg et al). 2003;146:e19
- Inflammation as a therapeutic target: a unique role for abciximab (Kereiakes). 2003;146:S1-4
- Percutaneous coronary interventions in patients with renal insufficiency: a high-risk, under-studied cohort (Steinhubl). 2003;146:213-14 (Editorial)
- Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions (Best et al). 2003;146:345-50

ACE inhibitors; see Angiotensin-converting enzyme inhibitors

Acetylcysteine

- Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography (Oldemeyer et al). 2003;146:e23

Acute coronary syndromes; see Angina, unstable; Myocardial infarction; Myocardial ischemia

Adaptation, physiological

- The 6-minute walk test: how important is the learning effect? (Wu et al). 2003;146:129-33

Adenosine

- A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study (Kopecky et al). 2003;146:146-52
- Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment (Murtagh et al). 2003;146:99-105

Adrenergic beta-antagonists

- Are β -blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials (Haas et al). 2003;146:848-53
- Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF (János et al). 2003;146:721-8

Advertising

- Pharmaceutical advertising versus research spending: are profits more important than patients? (Mukherjee and Topol). 2003;146:563-4 (Editorial)

Aged

- Baseline comorbidities and treatment strategy in elderly patients are associated with outcome of cardiogenic shock in a community-based population (Tedesco et al). 2003;146:472-8
- Heart failure and the elderly: disease diversity, data, and delivery of care (Alexander and Biswas). 2003;146:194-6 (Editorial)
- Impact of age on procedural and 1-year outcome in percutaneous transluminal coronary angioplasty: a report from the NHLBI Dynamic Registry (Cohen et al). 2003;146:513-19
- Is geography destiny? Illuminating the survival advantage of elderly patients in New England after acute myocardial infarction (Ayanian). 2003;146:207-9 (Editorial)
- Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study (Krumholz et al). 2003;146:839-47
- Most hospitalized older persons do not meet the enrollment

criteria for clinical trials in heart failure (Masoudi et al). 2003;146:250-7

- Pacemaker therapy in very elderly patients: long-term survival and prognostic parameters (Schmidt et al). 2003;146:908-13
- Pacing in elderly patients (Jahangir and Shen). 2003;146:750-3 (Editorial)

Regional variation in the treatment and outcomes of myocardial infarction: investigating New England's advantage (Krumholz et al). 2003;146:242-9

Alteplase

- One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction (Sinnaeve et al). 2003;146:27-32

American College of Cardiology

- Highlights from the American College of Cardiology Annual Scientific Sessions 2003: March 28 to April 2, 2003 (Petersen et al). 2003;146:19-26 (Meetings)

Amlodipine

- Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine (Wijcysundera et al). 2003;146:291-7

Angina, unstable; see also Myocardial ischemia

- Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study) (Huynh et al). 2003;146:668-73
- Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines (Antman). 2003;146:S18-22
- Impact of angina burden and other factors on treatment satisfaction after acute coronary syndromes (Beinart et al). 2003;146:646-52

Angina pectoris

- Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease (Mozaffarian et al). 2003;146:1015-22
- Biphasic relaxation-frequency relations in patients with effort angina pectoris: a new marker of myocardial demand ischemia (Umeda et al). 2003;146:75-83
- Diagnostic coronary angiography induces a systemic inflammatory response in patients with stable angina (Goldberg et al). 2003;146:819-23
- Enhanced External Counterpulsation (EECP): enough evidence to support this and the next wave? (Blazing and Crawford). 2003;146:383-4 (Editorial)
- Enhanced External Counterpulsation for the relief of angina in patients with diabetes: safety, efficacy and 1-year clinical outcomes (Linnemeier et al). 2003;146:453-8

Angiography

- Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography (Oldemeyer et al). 2003;146:e23
- Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the Thrombolysis In Myocardial Infarction (TIMI) 14 trial (Murphy et al). 2003;146:42-7
- Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events (Ricciardi et al). 2003;146:507-12
- Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon (Beltrame et al). 2003;146:84-90
- Diagnostic coronary angiography induces a systemic inflammatory response in patients with stable angina (Goldberg et al). 2003;146:819-23

Angioplasty

- Analysis of the institutional volume-outcome relations for balloon angioplasty and stenting in the stent era in California (Brown). 2003;146:1071-6
- Danish multicenter randomized study on fibrinolytic therapy

*July, pp. 1-188; August, pp. 189-376; September, pp. 377-560; October, part 1, pp. 561-746; part 2, pp. 51-530; November pp. 747-928; December, pp. 929-1146.

- versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2) (Andersen et al). 2003;146:234-41 (Trial design)
- Volume as a surrogate for percutaneous coronary intervention quality: is this the right measuring stick? (Brindis et al). 2003;146:932-4 (Editorial)
- Angioplasty, transluminal, percutaneous coronary**
- A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study (Kopecky et al). 2003;146:146-52
- Impact of age on procedural and 1-year outcome in percutaneous transluminal coronary angioplasty: a report from the NHLBI Dynamic Registry (Cohen et al). 2003;146:513-19
- Primary percutaneous transluminal coronary angioplasty accelerates early myocardial reperfusion compared to thrombolytic therapy in patients with acute myocardial infarction (Zeymer et al). 2003;146:686-91
- Angiotensin-converting enzyme inhibitors**
- Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAM) trial (Latini et al). 2003;146:e2
- Antioxidants**
- Endothelial dysfunction: clinical strategies for treating oxidant stress (Fenster et al). 2003;146:218-26 (Curriculum cardiol.)
- Improvement of peripheral endothelial dysfunction by acute vitamin C application: different effects in patients with coronary artery disease, ischemic, and dilated cardiomyopathy (Erbs et al). 2003;146:280-5
- Aortic coarctation**
- Self- and balloon-expandable stent implantation for severe native coarctation of aorta in adults (Tyagi et al). 2003;146:920-8
- Aortic valve diseases; see Heart valve diseases**
- Arginine vasopressin**
- Vasopressin: a new target for the treatment of heart failure (Lee et al). 2003;146:9-18 (Progress cardiol.)
- Arrhythmia; see also Atrial fibrillation**
- Annual distribution of ventricular tachycardias and ventricular fibrillation (Müller et al). 2003;146:1061-5
- Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside (De Caterina et al). 2003;146:420-30 (Progress cardiol.)
- Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure (Behling et al). 2003;146:494-500
- Death in patients with permanent pacemakers for sick sinus syndrome (Flaker et al). 2003;146:887-93
- Heart rate variability in chronic heart failure: target for therapy? (Sueta). 2003;146:385-7 (Editorial)
- Hiccup as an electrocardiographic artifact simulating arrhythmias (Cheng) (Letter); (Márquez and Pastelin) (Reply). 2003;146:e15, e16
- Left bundle branch block is not equivalent to "absent septal q wave" (Spodick). 2003;146:e9 (Letter)
- Pacemaker therapy in very elderly patients: long-term survival and prognostic parameters (Schmidt et al). 2003;146:908-13
- Pacing in elderly patients (Jahangir and Shen). 2003;146:750-3 (Editorial)
- Prognostic significance of morphometric endomyocardial biopsy analysis in patients with idiopathic dilated cardiomyopathy (Grimm et al). 2003;146:372-6
- The winter's tale—and toll (Williams and Zipes). 2003;146:941-3 (Editorial)
- Arteriosclerosis**
- Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease (Herrington et al). 2003;146:662-7
- Effect of transdermal nitroglycerin on inflammatory mediators in patients with peripheral atherosclerotic vascular disease (Berrazueta et al). 2003;146:e14
- Inflammation in atherosclerosis: causal or casual? The need for randomized trials (Meir et al). 2003;146:199-202 (Editorial)
- Loss of bone marrow-derived vascular progenitor cells leads to inflammation and atherosclerosis (Goldschmidt-Clermont). 2003;146:S5-12
- Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate (Deutschman et al). 2003;146:62-8
- Valvular and thoracic aortic calcium as a marker of the extent and severity of angiographic coronary artery disease (Yamamoto et al). 2003;146:153-9
- Aspirin**
- Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the PLavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial (Serebruany et al). 2003;146:713-20
- Atherectomy, coronary**
- Effect of plaque debulking before stent implantation on in-stent neointimal proliferation: a serial 3-dimensional intravascular ultrasound study (Takeda et al). 2003;146:175-82
- Atorvastatin**
- Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHES) (Ballantyne et al). 2003;146:862-9
- Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment (tule et al). 2003;146:e21
- Atrial fibrillation**
- Circadian variation of arrhythmia onset patterns in patients with persistent atrial fibrillation (Mitchell et al). 2003;146:902-7
- Evaluation of the dofetilide risk-management program (Allen LaPointe et al). 2003;146:894-901
- Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials (Connolly et al). 2003;146:489-93
- Therapeutic strategy in atrial fibrillation (Fauchier and Fauchier) (Letter); (AFFIRM Investigators) (Reply). 2003;146:e24, e25
- Transesophageal echocardiography before cardioversion of recurrent atrial fibrillation: does absence of previous atrial thrombi preclude the need of a repeat test? (Shen et al). 2003;146:741-5
- Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V) (Halperin and SPORTIF Executive Steering Committee). 2003;146:431-8 (Trial design)
- Azimilide**
- Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials (Connolly et al). 2003;146:489-93
- B**
- B-type natriuretic peptide; see Natriuretic peptide, brain**
- Baroreflex**
- Effect of n-3 fatty acids on heart rate variability and baroreflex sensitivity in middle-aged subjects (Geelen et al). 2003;146:e4
- beta-Blockers; see Adrenergic beta-antagonists**
- Biological markers**
- "Mirror-lake" serial relationship of electrocardiographic and bio-

chemical indices for the detection of reperfusion and the prediction of salvage in patients with acute myocardial infarction (Jurlander et al). 2003;146:757-63 (Progress cardiol.)
Noninvasive assessment of reperfusion therapy: slow progress toward a worthwhile goal (de Lemos and Morrow). 2003; 146:747-9 (Editorial)

Biopsy

Prognostic significance of morphometric endomyocardial biopsy analysis in patients with idiopathic dilated cardiomyopathy (Grimm et al). 2003;146:372-6

Blood glucose

Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention (Muhlestein et al). 2003;146:351-8

Subclinical diabetes mellitus: is it really "sub-clinical"? (Keebler and McGuire). 2003;146:210-12 (Editorial)

Blood pressure

Are heart rate and blood pressure responses to mental stress predictive of clinical cardiovascular events? The answer varies by coronary artery disease syndrome (Sheps and Bragdon). 2003;146:197-8 (Editorial)

False-positive exercise echocardiograms: impact of sex and blood pressure response (Shin et al). 2003;146:914-19

Heart rate and blood pressure responses to mental stress and clinical cardiovascular events in men and women after coronary artery bypass grafting: the Post Coronary Artery Bypass Graft (Post-CABG) biobehavioral study (Herd et al). 2003;146:273-9

Body weight

Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial (Goldberg et al). 2003; 146:705-12

Reduction in obesity and coronary risk factors after high caloric exercise training in overweight coronary patients (Savage et al). 2003;146:317-23

Brachytherapy

Additional stenting promotes intimal proliferation and compromises the results of intravascular radiation therapy: an intravascular ultrasound study (Cheneau et al). 2003;146:142-5

Intracoronary brachytherapy for the prevention of restenosis after percutaneous coronary revascularization (Sheppard et al). 2003;146:775-86 (Curriculum cardiol.)

Bundle-branch block

Left bundle branch block is not equivalent to "absent septal q wave" (Spodick). 2003;146:e9 (Letter)

C

C-reactive protein

C-reactive protein elevation independently influences the procedural success of percutaneous balloon mitral valve commissurotomy (Krasuski et al). 2003;146:1099-104

Risk factors for "major" embolic events in hospitalized patients with infective endocarditis (Durante Mangoni et al). 2003; 146:311-16

Vegetations in endocarditis: big is bad, but is there more to it? (Cabell and Fowler). 2003;146:189-90 (Editorial)

CABG; see Coronary artery bypass

Calcium

Electron beam CT versus helical CT scans for assessing coronary calcification: current utility and future directions (Nasir et al). 2003;146:969-77 (Progress cardiol.)

Valvular and thoracic aortic calcium as a marker of the extent and severity of angiographic coronary artery disease (Yamamoto et al). 2003;146:153-9

Calcium-channel blockers

Mibefradil: "has the baby been thrown out with the bath water?" (Beltrame et al). 2003;146:e3 (Letter)

Canada

Are some patients in Canada treated more equally than others? The Orwell prophecy (Alter). 2003;146:938-40 (Editorial)

Universal health insurance coverage does not eliminate inequities in access to cardiac procedures after acute myocardial infarction (Pilote et al). 2003;146:1030-7

Candesartan

Choice of treatment: outcomes and treatment goals (Temple). 2003;146:565-7 (Editorial)

Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease (Kondo et al). 2003;146:e20

Of millimeterology and cannibalism: comparative antihypertensive efficacy of angiotensin receptor blockers (Messerli). 2003;146:568-9 (Editorial)

Cardiogenic shock; see Shock, cardiogenic

Cardiomyopathy, congestive

Left ventricular wall stress as a direct correlate of cardiomyocyte apoptosis in patients with severe dilated cardiomyopathy (Di Napoli et al). 2003;146:1105-11

Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine (Wijesundera et al). 2003;146:291-7

Prognostic significance of morphometric endomyocardial biopsy analysis in patients with idiopathic dilated cardiomyopathy (Grimm et al). 2003;146:372-6

Cardiomyopathy, hypertrophic

Impact of infarct size on clinical and echocardiographic outcome in patients undergoing nonsurgical septal reduction therapy (Chang et al). 2003;146:1112-14

Cardiovascular diseases

Identification, course, and treatment of depression after admission for a cardiac condition: rationale and patient characteristics for the Identifying Depression As a Comorbid Condition (IDACC) project (Cheek et al). 2003;146:978-84 (Trial design)

Screening for early detection of cardiovascular disease in asymptomatic individuals (Cohn et al). 2003;146:679-85

Cardioversion; see Electric countershock

Case-control studies

The nested case-control study in cardiology (Essebag et al). 2003;146:581-90 (Curriculum cardiol.)

Cerebrovascular accident

Acute coronary syndromes in patients with prior cerebrovascular events: lessons from the Euro-Heart Survey of Acute Coronary Syndromes (Hasdai et al). 2003;146:832-8

Is left atrial appendage occlusion during routine coronary artery bypass graft surgery useful for stroke prevention? (Stöckelberger et al). 2003;146:e26 (Letter)

Chlamydia pneumoniae

Joint effects of *Chlamydia pneumoniae* infection and classic coronary risk factors on risk of acute myocardial infarction (Kinjo et al). 2003;146:324-30

Neopterin levels in patients with coronary artery disease are independent of *Chlamydia pneumoniae* seropositivity (Smith et al). 2003;146:69-74

Serologic markers of persistent *Chlamydia pneumoniae* infection and long-term prognosis after successful coronary stenting (Zairis et al). 2003;146:1082-9

Cholesterol; see Lipids and Lipoproteins

Circadian rhythm

Circadian variation of arrhythmia onset patterns in patients with persistent atrial fibrillation (Mitchell et al). 2003;146:902-7

Clinical trials

Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality (Gombert-Maitland et al). 2003;146:398-403 (Curriculum cardiol.)

Heart failure and the elderly: disease diversity, data, and delivery of care (Alexander and Biswas). 2003;146:194-6 (Editorial)

Highlights from the American College of Cardiology Annual

- Scientific Sessions 2003: March 28 to April 2, 2003 (Petersen et al). 2003;146:19-26 (Meetings)
- Hypertensive patients' willingness to participate in placebo-controlled trials: implications for recruitment efficiency (Halpern et al). 2003;146:985-92 (Trial design)
- Is there evidence of implicit exclusion criteria for elderly subjects in randomized trials? Evidence from the GUSTO-1 study (Krumholz et al). 2003;146:839-47
- Matters of the heart: assessing the cardiovascular safety of new drugs (Konstam). 2003;146:561-2 (Editorial)
- Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure (Masoudi et al). 2003;146:250-7
- Patients' willingness to participate in placebo-controlled trials of antihypertensive therapy (Al-Khatib and Biswas). 2003;146:944-5 (Editorial)
- Clopidogrel**
- Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the PLavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial (Serebruany et al). 2003;146:713-20
- Coarctation of aorta; see Aortic coarctation**
- Comorbidity**
- Baseline comorbidities and treatment strategy in elderly patients are associated with outcome of cardiogenic shock in a community-based population (Tedesco et al). 2003;146:472-8
- Cognitive and somatic symptoms of depression are associated with medical comorbidity in patients after acute myocardial infarction (Watkins et al). 2003;146:48-54
- Identification, course, and treatment of depression after admission for a cardiac condition: rationale and patient characteristics for the Identifying Depression As a Comorbid Condition (IDACC) project (Cheok et al). 2003;146:978-84 (Trial design)
- Computed tomography; see Tomography, x-ray computed**
- Congestive heart failure; see Heart failure, congestive**
- Contrast media**
- Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography (Oldemeyer et al). 2003;146:e23
- Coronary artery bypass**
- Are heart rate and blood pressure responses to mental stress predictive of clinical cardiovascular events? The answer varies by coronary artery disease syndrome (Sheps and Bragdon). 2003;146:197-8 (Editorial)
- Comparison of health-related quality-of-life outcomes of men and women after coronary artery bypass surgery through 1 year: findings from the POST CABG Biobehavioral Study (Lindquist et al). 2003;146:1038-44
- Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft (Leborgne et al). 2003;146:501-6
- Heart rate and blood pressure responses to mental stress and clinical cardiovascular events in men and women after coronary artery bypass grafting: the Post Coronary Artery Bypass Graft (Post-CABG) biobehavioral study (Herd et al). 2003;146:273-9
- Is left atrial appendage occlusion during routine coronary artery bypass graft surgery useful for stroke prevention? (Stöllberger et al). 2003;146:e26 (Letter)
- Obesity and the risk of early and late mortality after coronary artery bypass graft surgery (Kim et al). 2003;146:555-60
- Right ventricular function before and after an uncomplicated coronary artery bypass graft as assessed by pulsed wave Doppler tissue imaging of the tricuspid annulus (Alam et al). 2003;146:520-6
- Women and outcomes of coronary artery bypass surgery: do we have an answer? (Vaccarino). 2003;146:935-7 (Editorial)
- Coronary circulation**

- Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction (Prasad et al). 2003;146:549-54
- Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon (Beltrame et al). 2003;146:84-90
- Diabetes mellitus and acute myocardial infarction: more data supporting a poorer microvasculature reperfusion (Moreno et al). 2003;146:e6 (Letter)
- Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment (Murtagh et al). 2003;146:99-105
- Statin use is associated with enhanced collateralization of severely diseased coronary arteries (Pourati et al). 2003;146:876-81
- Coronary disease**
- Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease (Mozaffarian et al). 2003;146:1015-22
- Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease (Herrington et al). 2003;146:662-7
- Assessing risk for coronary heart disease: beyond Framingham (Cobb et al). 2003;146:572-80 (Editorial)
- Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS) (Shlipak et al). 2003;146:870-5
- Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial (Hsia et al). 2003;146:439-45
- Neopterin levels in patients with coronary artery disease are independent of *Chlamydia pneumoniae* seropositivity (Smith et al). 2003;146:69-74
- Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate (Deutschman et al). 2003;146:62-8
- Role of lipid and lipoprotein profiles in risk assessment and therapy (Ballantyne and Hoogeveen). 2003;146:227-33 (Progress cardiol.)
- Valvular and thoracic aortic calcium as a marker of the extent and severity of angiographic coronary artery disease (Yamamoto et al). 2003;146:153-9
- Coronary disease, diagnosis**
- Addition of right-sided and posterior precordial leads during stress testing (Shry et al). 2003;146:1090-4
- Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events (Ricciardi et al). 2003;146:507-12
- Electron beam CT versus helical CT scans for assessing coronary calcification: current utility and future directions (Nasir et al). 2003;146:969-77 (Progress cardiol.)
- Coronary disease, therapy**
- Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease (Kondo et al). 2003;146:e20
- Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy) (Serebruany et al). 2003;146:91-8
- Improving quality of care in the real world: efficacy versus effectiveness? (Mukherjee and Eagle). 2003;146:946-7 (Editorial)
- Quality of care for secondary prevention for patients with coronary heart disease: results of the Hastening the Effective Application of Research through Technology (HEART) trial (Goff et al). 2003;146:1045-51
- Reduction in obesity and coronary risk factors after high caloric exercise training in overweight coronary patients (Savage et al). 2003;146:317-23
- Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis (Bourque et al). 2003;146:621-7

Statin use is associated with enhanced collateralization of severely diseased coronary arteries (Pourati et al). 2003;146:876-81

The cholesteryl ester transfer protein *Taq1B* gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease (Carlquist et al). 2003;146:1007-14

Coronary restenosis

Additional stenting promotes intimal proliferation and compromises the results of intravascular radiation therapy: an intravascular ultrasound study (Cheneau et al). 2003;146:142-5

Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future (Leon and Bakhai). 2003;146: S13-17

4G/5G Polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting (Böttiger et al). 2003;146:855-61

Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STERO trial (Hausleiter et al). 2003;146:882-6

Intracoronary brachytherapy for the prevention of restenosis after percutaneous coronary revascularization (Sheppard et al). 2003;146:775-86 (Curriculum cardi.)

Percutaneous coronary intervention: historical perspectives, current status, and future directions (Arjomand et al). 2003;146:787-96 (Curriculum cardi.)

Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study (Takagi et al). 2003;146:e5

Prospective randomized comparison of early and late results of 4 different stent designs (Sick et al). 2003;146:134-41

Restenosis in Intervened Coronaries with Hyperhomocysteinemia (RICH) (Kojouharian et al). 2003;146:1077-81

Correspondence; see Letters to the Editor

Counterpulsation

Enhanced External Counterpulsation (EECP): enough evidence to support this and the next wave? (Blazing and Crawford). 2003;146:383-4 (Editorial)

Enhanced External Counterpulsation for the relief of angina in patients with diabetes: safety, efficacy and 1-year clinical outcomes (Linnemeier et al). 2003;146:453-8

Cyclooxygenase inhibitors

Matters of the heart: assessing the cardiovascular safety of new drugs (Konstam). 2003;146:561-2 (Editorial)

Pharmaceutical advertising versus research spending: are profits more important than patients? (Mukherjee and Topol). 2003;146:563-4 (Editorial)

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program (Weir et al). 2003;146:591-604 (Progress cardi.)

Cysteine

Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine (Melenovsky et al). 2003;146:e1

D

Death, sudden, cardiac; see also Mortality

Annual distribution of ventricular tachycardias and ventricular fibrillation (Müller et al). 2003;146:1061-5

Cardiac pathologic findings reveal a high rate of sudden cardiac death of undetermined etiology in younger women (Chugh et al). 2003;146:635-9

The winter's tale—and toll (Williams and Zipes). 2003;146: 941-3 (Editorial)

Defibrillators, implantable

Endocardial pacemaker or defibrillator leads with infected vegetations: a single-center experience and consequences of transvenous extraction (Meier-Ewert et al). 2003;146:339-44

Worldwide evaluation of a defibrillation lead with a small geometric electrode surface for high-impedance pacing (Vollmann et al). 2003;146:1066-70

Depression

Cognitive and somatic symptoms of depression are associated with medical comorbidity in patients after acute myocardial infarction (Watkins et al). 2003;146:48-54

Depression and increased myocardial ischemic activity in patients with ischemic heart disease (Jiang et al). 2003;146: 55-61

Identification, course, and treatment of depression after admission for a cardiac condition: rationale and patient characteristics for the Identifying Depression As a Comorbid Condition (IDACC) project (Cheek et al). 2003;146:978-84 (Trial design)

Diabetes mellitus

Are β -blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials (Haas et al). 2003;146:848-53

Diabetes mellitus and acute myocardial infarction: more data supporting a poorer microvasculature reperfusion (Moreno et al). 2003;146:e6 (Letter)

Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention (Muhlestein et al). 2003;146:351-8

Enhanced External Counterpulsation for the relief of angina in patients with diabetes: safety, efficacy and 1-year clinical outcomes (Linnemeier et al). 2003;146:453-8

Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study (Takagi et al). 2003;146:e5

Sex differences in survival after acute myocardial infarction in patients with diabetes mellitus (Worcester Heart Attack Study) (Crowley et al). 2003;146:824-31

Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy (Fragasso et al). 2003;146:e18

Subclinical diabetes mellitus: is it really "sub-clinical"? (Keebler and McGuire). 2003;146:210-12 (Editorial)

Diastole

Spectral pulsed tissue Doppler imaging in diastole: a tool to increase our insight in and assessment of diastolic relaxation of the left ventricle (De Boeck et al). 2003;146:411-19 (Progress cardi.)

Direct thrombin inhibitors

Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where? (Lincoff). 2003;146:S23-30

Dofetilide

Evaluation of the dofetilide risk-management program (Allen LaPointe et al). 2003;146:894-901

Drug therapy

Choice of treatment: outcomes and treatment goals (Temple). 2003;146:565-7 (Editorial)

Matters of the heart: assessing the cardiovascular safety of new drugs (Konstam). 2003;146:561-2 (Editorial)

Of millimetry and cannibalism: comparative antihypertensive efficacy of angiotensin receptor blockers (Messerli). 2003;146:568-9 (Editorial)

Pharmaceutical advertising versus research spending: are profits more important than patients? (Mukherjee and Topol). 2003;146:563-4 (Editorial)

Ductus arteriosus, patent

Vocal cord paralysis after transcatheter coil embolization of patent ductus arteriosus (Liang et al). 2003;146:367-71

E

Echocardiography

- Ejection fraction by echocardiography: the full monty or just a peep show? (Schiller). 2003;146:380-2 (Editorial)
- Prognostic implications of ejection fraction from linear echocardiographic dimensions: the Strong Heart Study (Devereux et al). 2003;146:527-34
- Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods (McGowan and Cleland). 2003;146:388-97 (Curriculum cardi.)
- Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure (Baker et al). 2003;146:736-40
- Screening for structural heart disease: time to stop listening and start looking (Alexander and Patel). 2003;146:570-1 (Editorial)
- Transesophageal echocardiography before cardioversion of recurrent atrial fibrillation: does absence of previous atrial thrombi preclude the need of a repeat test? (Shen et al). 2003;146:741-5

Echocardiography, Doppler

- Myocardial factor for timing of surgery in asymptomatic patients with mitral regurgitation (Stewart). 2003;146:5-8 (Editorial)
- Relationship of ventricular longitudinal function to contractile reserve in patients with mitral regurgitation (Haluska et al). 2003;146:183-8
- Right ventricular function before and after an uncomplicated coronary artery bypass graft as assessed by pulsed wave Doppler tissue imaging of the tricuspid annulus (Alam et al). 2003;146:520-6
- Spectral pulsed tissue Doppler imaging in diastole: a tool to increase our insight in and assessment of diastolic relaxation of the left ventricle (De Boeck et al). 2003;146:411-19 (Progress cardi.)

Echocardiography, stress

- False-positive exercise echocardiograms: impact of sex and blood pressure response (Shin et al). 2003;146:914-19

Editorials

- Are heart rate and blood pressure responses to mental stress predictive of clinical cardiovascular events? The answer varies by coronary artery disease syndrome (Sheps and Bragdon). 2003;146:197-8
- Are some patients in Canada treated more equally than others? The Orwell prophecy (Alter). 2003;146:938-40
- Assessing risk for coronary heart disease: beyond Framingham (Cobb et al). 2003;146:572-80
- Choice of treatment: outcomes and treatment goals (Temple). 2003;146:565-7
- Defining myocardial infarction: "Will the real myocardial infarction please stand up?" (Alpert). 2003;146:377-9
- Does race matter in heart failure? (Yancy). 2003;146:203-6
- Ejection fraction by echocardiography: the full monty or just a peep show? (Schiller). 2003;146:380-2
- Enhanced External Counterpulsation (EECP): enough evidence to support this and the next wave? (Blazing and Crawford). 2003;146:383-4
- Heart failure: how big is the problem? Who are the patients? What does the future hold? (Ansari and Massie). 2003;146:1-4
- Heart failure and the elderly: disease diversity, data, and delivery of care (Alexander and Biswas). 2003;146:194-6
- Heart rate variability in chronic heart failure: target for therapy? (Sueta). 2003;146:385-7
- Hippocrates and prognosis in heart failure: the challenge of static and dynamic measurements (Ventura and Mehra). 2003;146:215-17
- Improving quality of care in the real world: efficacy versus effectiveness? (Mukherjee and Eagle). 2003;146:946-7
- Inflammation in atherosclerosis: causal or casual? The need for randomized trials (Meir et al). 2003;146:199-202 (Editorial)

Is geography destiny? Illuminating the survival advantage of elderly patients in New England after acute myocardial infarction (Ayanian). 2003;146:207-9

Low molecular weight heparins for acute coronary syndrome: tackling the issues head-on (Antman). 2003;146:191-3

Matters of the heart: assessing the cardiovascular safety of new drugs (Konstam). 2003;146:561-2

Myocardial factor for timing of surgery in asymptomatic patients with mitral regurgitation (Stewart). 2003;146:5-8

New insight into clinical risk scores for patients with acute coronary syndromes (Morrow). 2003;146:754-6

Noninvasive assessment of reperfusion therapy: slow progress toward a worthwhile goal (de Lemos and Morrow). 2003;146:747-9

Of millimeterology and cannibalism: comparative antihypertensive efficacy of angiotensin receptor blockers (Messeri). 2003;146:568-9

Pacing in elderly patients (Jahangir and Shen). 2003;146:750-3

Patients' willingness to participate in placebo-controlled trials of antihypertensive therapy (Al-Khatib and Biswas). 2003;146:944-5

Percutaneous coronary interventions in patients with renal insufficiency: a high-risk, under-studied cohort (Steinhubl). 2003;146:213-14

Pharmaceutical advertising versus research spending: are profits more important than patients? (Mukherjee and Topol). 2003;146:563-4

Screening for structural heart disease: time to stop listening and start looking (Alexander and Patel). 2003;146:570-1

Subclinical diabetes mellitus: is it really "sub-clinical"? (Keebler and McGuire). 2003;146:210-12

The winter's tale—and toll (Williams and Zipes). 2003;146:941-3

Vegetations in endocarditis: big is bad, but is there more to it? (Cabell and Fowler). 2003;146:189-90

Volume as a surrogate for percutaneous coronary intervention quality: is this the right measuring stick? (Brindis et al). 2003;146:932-4

Where the rubber meets the road in pharmacogenetics: assessment of gene-environment interactions (Hauser and Allen). 2003;146:929-31

Women and outcomes of coronary artery bypass surgery: do we have an answer? (Vaccarino). 2003;146:935-7

Eicosapentaenoic acid

- Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS) (Yokoyama et al). 2003;146:613-20 (Trial design)

Ejection fraction; see Stroke volume**Elderly; see Aged****Electric countershock**

- Transesophageal echocardiography before cardioversion of recurrent atrial fibrillation: does absence of previous atrial thrombi preclude the need of a repeat test? (Shen et al). 2003;146:741-5

Electrocardiography

A modified Anderson-Wilkins electrocardiographic acuteness score for anterior or inferior myocardial infarction (Hedén et al). 2003;146:797-803 (Curriculum cardi.)

Addition of right-sided and posterior precordial leads during stress testing (Shry et al). 2003;146:1090-4

Clinical and angiographic characteristics of patients with combined anterior and inferior ST-segment elevation on the initial electrocardiogram during acute myocardial infarction (Sadanandan et al). 2003;146:653-61

Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy (Lockwood et al). 2003;146:640-5

Hiccup as an electrocardiographic artifact simulating arrhythmia

- mias (Cheng) (Letter); (Márquez and Pastelín) (Reply). 2003; 146:e15, e16
- Left bundle branch block is not equivalent to "absent septal q wave" (Spodick). 2003;146:e9 (Letter)
- "Mirror-lake" serial relationship of electrocardiographic and biochemical indices for the detection of reperfusion and the prediction of salvage in patients with acute myocardial infarction (Jurlander et al). 2003;146:757-63 (Progress cardiol.)
- Noninvasive assessment of reperfusion therapy: slow progress toward a worthwhile goal (de Lemos and Morrow). 2003; 146:747-9 (Editorial)
- Quantitative clinical assessment of chronic anterior myocardial infarction with delayed enhancement magnetic resonance imaging and QRS scoring (Engblom et al). 2003;146:359-66
- Embolism and thrombolysis**
- Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies (Kim and Becker). 2003;146:948-57 (Curriculum cardiol.)
- Risk factors for "major" embolic events in hospitalized patients with infective endocarditis (Durante Mangoni et al). 2003; 146:311-16
- Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program (Weir et al). 2003; 146:591-604 (Progress cardiol.)
- Vegetations in endocarditis: big is bad, but is there more to it? (Cabell and Fowler). 2003;146:189-90 (Editorial)
- Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V) (Halperin and SPORTIF Executive Steering Committee). 2003;146:431-8 (Trial design)
- Embolization, therapeutic**
- Vocal cord paralysis after transcatheter coil embolization of patent ductus arteriosus (Liang et al). 2003;146:367-71
- Endocarditis**
- Clinical profile of *Streptococcus agalactiae* native valve endocarditis (Rollán et al). 2003;146:1095-8
- Endocardial pacemaker or defibrillator leads with infected vegetations: a single-center experience and consequences of transvenous extraction (Meier-Ewert et al). 2003;146:339-44
- Risk factors for "major" embolic events in hospitalized patients with infective endocarditis (Durante Mangoni et al). 2003; 146:311-16
- Vegetations in endocarditis: big is bad, but is there more to it? (Cabell and Fowler). 2003;146:189-90 (Editorial)
- Endothelium, vascular**
- Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction (Prasad et al). 2003;146:549-54
- Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude (Kuvin et al). 2003;146: 168-74
- Endothelial dysfunction: clinical strategies for treating oxidant stress (Fenster et al). 2003;146:218-26 (Curriculum cardiol.)
- Improvement of peripheral endothelial dysfunction by acute vitamin C application: different effects in patients with coronary artery disease, ischemic, and dilated cardiomyopathy (Erbs et al). 2003;146:280-5
- Enhanced External Counterpulsation; see Counterpulsation**
- Enoxaparin**
- Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study (Ferguson et al). 2003;146:628-34
- Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial (Michalis et al). 2003;146:304-10

- Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies (Spinler et al). 2003;146:33-41
- Epidemiologic research design**
- The nested case-control study in cardiology (Essebag et al). 2003;146:581-90 (Curriculum cardiol.)
- Eptifibatide**
- A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes (Roe et al). 2003;146:993-8
- Ethanol**
- Impact of infarct size on clinical and echocardiographic outcome in patients undergoing nonsurgical septal reduction therapy (Chang et al). 2003;146:1112-14
- Exercise test**
- Addition of right-sided and posterior precordial leads during stress testing (Shry et al). 2003;146:1090-4
- Biphasic relaxation-frequency relations in patients with effort angina pectoris: a new marker of myocardial demand ischemia (Umeda et al). 2003;146:75-83
- Don't shoot the messenger: the 6-minute walk test is a useful outcome measure in exercise trials (Witham and McMurdo). 2003;146:e7 (Letter)
- False-positive exercise echocardiograms: impact of sex and blood pressure response (Shin et al). 2003;146:914-19
- Improved myocardial performance during repetitive exercise testing: the role of extracellular superoxide dismutase activity in a model of exercise-induced myocardial preconditioning (Michaelides et al). 2003;146:160-7
- Normalization for peak oxygen uptake increases the prognostic power of the ventilatory response to exercise in patients with chronic heart failure (Guazzi et al). 2003;146:542-8
- The 6-minute walk test: how important is the learning effect? (Wu et al). 2003;146:129-33
- Exercise therapy**
- Reduction in obesity and coronary risk factors after high caloric exercise training in overweight coronary patients (Savage et al). 2003;146:317-23
- F**
- Fatty acids, omega-3**
- Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside (De Caterina et al). 2003;146:420-30 (Progress cardiol.)
- Effect of n-3 fatty acids on heart rate variability and baroreflex sensitivity in middle-aged subjects (Geelen et al). 2003;146:e4
- Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS) (Yokoyama et al). 2003;146:613-20 (Trial design)
- Fibrinolytic therapy; see Thrombolytic therapy**
- Folic acid**
- Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine (Melenovsky et al). 2003;146:e1
- Framingham Heart Study**
- Assessing risk for coronary heart disease: beyond Framingham (Cobb et al). 2003;146:572-80 (Editorial)
- G**
- Genetics**
- Arg389Gly polymorphism of the human β 1-adrenergic receptor in patients with nonfatal acute myocardial infarction (Iwai et al). 2003;146:106-9
- Association between factor V Leiden, prothrombin G20210A,

- and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies (Kim and Becker). 2003;146:948-57 (Curriculum cardiol.)
- 4G/5G Polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting (Böttiger et al). 2003;146:855-61
- The cholesteryl ester transfer protein *Taq1B* gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease (Carlquist et al). 2003;146:1007-14
- Where the rubber meets the road in pharmacogenetics: assessment of gene-environment interactions (Hauser and Allen). 2003;146:929-31 (Editorial)
- Glycoprotein IIb/IIIa inhibitors; see Platelet aggregation inhibitors**

H

Health care quality, access, and evaluation

- Are some patients in Canada treated more equally than others? The Orwell prophecy (Alter). 2003;146:938-40 (Editorial)
- Changing the model of care for patients with acute coronary syndromes (Roe et al). 2003;146:605-12 (Progress cardiol.)
- Comparison of treatment and outcomes for patients with acute myocardial infarction in Minneapolis/St. Paul, Minnesota, and Göteborg, Sweden (Herlitz et al). 2003;146:1023-9
- Improving quality of care in the real world: efficacy versus effectiveness? (Mukherjee and Eagle). 2003;146:946-7 (Editorial)
- Is geography destiny? Illuminating the survival advantage of elderly patients in New England after acute myocardial infarction (Ayanian). 2003;146:207-9 (Editorial)
- Mortality trends for 23,505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997 (Baker et al). 2003;146:258-64
- Quality of care for secondary prevention for patients with coronary heart disease: results of the Hastening the Effective Application of Research through Technology (HEART) trial (Goff et al). 2003;146:1045-51
- Regional variation in the treatment and outcomes of myocardial infarction: investigating New England's advantage (Krumholz et al). 2003;146:242-9
- Universal health insurance coverage does not eliminate inequities in access to cardiac procedures after acute myocardial infarction (Pilote et al). 2003;146:1030-7

Health surveys

- Heart failure: how big is the problem? Who are the patients? What does the future hold? (Ansari and Massie). 2003;146:1-4 (Editorial)
- Prevalence of self-reported heart failure among US adults: results from the 1999 National Health Interview Survey (NI). 2003;146:121-8

Heart failure, congestive

- Does race matter in heart failure? (Yancy). 2003;146:203-6 (Editorial)
- Heart failure: how big is the problem? Who are the patients? What does the future hold? (Ansari and Massie). 2003;146:1-4 (Editorial)
- Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function (Ansari et al). 2003;146:115-20
- Prevalence of self-reported heart failure among US adults: results from the 1999 National Health Interview Survey (NI). 2003;146:121-8
- Survival rates are similar between African American and white patients with heart failure (Dunlap et al). 2003;146:265-72

Heart failure, congestive, drug therapy

- Are β -blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic

heart failure? A meta-analysis of large-scale clinical trials (Haas et al). 2003;146:848-53

Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure (Behling et al). 2003;146:494-500

Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure (De Tommasi et al). 2003;146:e17

Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the PLavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial (Serebruany et al). 2003;146:713-20

Heart rate variability in chronic heart failure: target for therapy? (Sueta). 2003;146:385-7 (Editorial)

Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF (János et al). 2003;146:721-8

Vasopressin: a new target for the treatment of heart failure (Lee et al). 2003;146:9-18 (Progress cardiol.)

Heart failure, congestive, prognosis

Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure (Isnard et al). 2003;146:729-35

Hippocrates and prognosis in heart failure: the challenge of static and dynamic measurements (Ventura and Mehra). 2003;146:215-17 (Editorial)

Is heart failure survival improving? Evidence from 2323 elderly patients hospitalized between 1989-2000 (Feinglass et al). 2003;146:111-14

Mortality trends for 23,505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997 (Baker et al). 2003;146:258-64

Normalization for peak oxygen uptake increases the prognostic power of the ventilatory response to exercise in patients with chronic heart failure (Guazzi et al). 2003;146:542-8

Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction (Kerzner et al). 2003;146:286-90

Serial versus isolated assessment of clinical and instrumental parameters in heart failure: prognostic and therapeutic implications (Grigioni et al). 2003;146:298-303

Heart failure, congestive, therapy

Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds—the TEMISTOCLE study (Di Lenarda et al). 2003;146:e12

Don't shoot the messenger: the 6-minute walk test is a useful outcome measure in exercise trials (Witham and McMurdo). 2003;146:e7 (Letter)

Heart failure and the elderly: disease diversity, data, and delivery of care (Alexander and Biswas). 2003;146:194-6 (Editorial)

Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure (Masoudi et al). 2003;146:250-7

Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial (Goldberg et al). 2003;146:705-12

Thermal hydrotherapy improves quality of life and hemodynamic function in patients with chronic heart failure (Michalsen et al). 2003;146:e11

Heart rate

Are heart rate and blood pressure responses to mental stress predictive of clinical cardiovascular events? The answer varies by coronary artery disease syndrome (Sheps and Bragdon). 2003;146:197-8 (Editorial)

Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure (Behling et al). 2003;146:494-500

Effect of n-3 fatty acids on heart rate variability and baroreflex

sensitivity in middle-aged subjects (Geelen et al). 2003;146:e4

Heart rate and blood pressure responses to mental stress and clinical cardiovascular events in men and women after coronary artery bypass grafting: the Post Coronary Artery Bypass Graft (Post-CABG) biobehavioral study (Herd et al). 2003;146:273-9

Heart rate variability in chronic heart failure: target for therapy? (Sueta). 2003;146:385-7 (Editorial)

Heart septum

Impact of infarct size on clinical and echocardiographic outcome in patients undergoing nonsurgical septal reduction therapy (Chang et al). 2003;146:1112-14

Heart valve diseases

C-reactive protein elevation independently influences the procedural success of percutaneous balloon mitral valve commissurotomy (Krasuski et al). 2003;146:1099-104

Cardiac papillary fibroblastoma: a comprehensive analysis of 725 cases (Gowda et al). 2003;146:404-10 (Curriculum cardiol.)

Clinical profile of *Streptococcus agalactiae* native valve endocarditis (Rollán et al). 2003;146:1095-8

Does the type of prosthesis influence early left ventricular mass regression after aortic valve replacement? Assessment with magnetic resonance imaging (Sensky et al). 2003;146:e13

Myocardial factor for timing of surgery in asymptomatic patients with mitral regurgitation (Stewart). 2003;146:5-8 (Editorial)

Relationship of ventricular longitudinal function to contractile reserve in patients with mitral regurgitation (Haluska et al). 2003;146:183-8

Hemodynamics

Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude (Kuvín et al). 2003;146:168-74

Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon (Beltrame et al). 2003;146:84-90

Role of incremental doses of intracoronary adenosine for fractional flow reserve assessment (Murtagh et al). 2003;146:99-105

Thermal hydrotherapy improves quality of life and hemodynamic function in patients with chronic heart failure (Michalsen et al). 2003;146:e11

Heparin

Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE) (Budaj et al). 2003;146:999-1006

Low molecular weight heparins for acute coronary syndrome: tackling the issues head-on (Antman). 2003;146:191-3 (Editorial)

Platelet activation after stenting with heparin-coated versus noncoated stents (Gurbel and Bliden). 2003;146:e10

Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies (Spinler et al). 2003;146:33-41

Hiccup

Hiccup as an electrocardiographic artifact simulating arrhythmias (Cheng) (Letter); (Márquez and Pastelin) (Reply). 2003;146:e15, e16

Homocysteine

Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine (Melenovsky et al). 2003;146:e1

Restenosis in Intervened Coronaries with Hyperhomocysteinemia (RICH) (Kojouharian et al). 2003;146:1077-81

Hormone replacement therapy

Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS) (Shlipak et al). 2003;146:870-5

Hospital units

Analysis of the institutional volume-outcome relations for bal-

loon angioplasty and stenting in the stent era in California (Brown). 2003;146:1071-6

Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worlds—the TEMISTOCLE study (Di Lenarda et al). 2003;146:e12

Volume as a surrogate for percutaneous coronary intervention quality: is this the right measuring stick? (Brindis et al). 2003;146:932-4 (Editorial)

Hydrotherapy

Thermal hydrotherapy improves quality of life and hemodynamic function in patients with chronic heart failure (Michalsen et al). 2003;146:e11

Hydroxymethylglutaryl-CoA reductase inhibitors

Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS) (Ballantyne et al). 2003;146:862-9

Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment (tule et al). 2003;146:e21

Statin use is associated with enhanced collateralization of severely diseased coronary arteries (Pourati et al). 2003;146:876-81

The cholesteryl ester transfer protein *Taq1B* gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease (Carlquist et al). 2003;146:1007-14

Hyperglycemia

Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction (Ishihara et al). 2003;146:674-8

Hyperlipidemia and hypercholesterolemia

Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS) (Ballantyne et al). 2003;146:862-9

Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS) (Yokoyama et al). 2003;146:613-20 (Trial design)

Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment (tule et al). 2003;146:e21

Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol (Bersot et al). 2003;146:1052-60

Hypertension

Hypertensive patients' willingness to participate in placebo-controlled trials: implications for recruitment efficiency (Halpern et al). 2003;146:985-92 (Trial design)

Patients' willingness to participate in placebo-controlled trials of antihypertensive therapy (Al-Khatib and Biswas). 2003;146:944-5 (Editorial)

Inflammation

Diagnostic coronary angiography induces a systemic inflammatory response in patients with stable angina (Goldberg et al). 2003;146:819-23

Effect of transdermal nitroglycerin on inflammatory mediators in patients with peripheral atherosclerotic vascular disease (Berrazuela et al). 2003;146:e14

Inflammation as a therapeutic target: a unique role for abciximab (Kerckhakes). 2003;146:S1-4

Inflammation in atherosclerosis: causal or casual? The need for randomized trials (Meir et al). 2003;146:199-202 (Editorial)

Loss of bone marrow-derived vascular progenitor cells leads to

- inflammation and atherosclerosis (Goldschmidt-Clermont). 2003;146:S5-12
- Preprocedural white blood cell count and death after percutaneous coronary intervention (Gurm et al). 2003;146:692-8
- Intra-aortic balloon pumping**
- Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on a 12-month survival in the SHOCK trial (French et al). 2003;146:804-10
- Intravascular ultrasonography; see Ultrasonography, interventional**
- Ischemic heart disease; see Myocardial ischemia**

K**Kidney diseases**

- Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography (Oldemeyer et al). 2003;146:e23
- Percutaneous coronary interventions in patients with renal insufficiency: a high-risk, under-studied cohort (Steinhilber). 2003;146:213-14 (Editorial)
- Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies (Spinler et al). 2003;146:33-41
- Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions (Best et al). 2003;146:345-50

L**Learning effect; see Adaptation, physiological**
Letters to the Editor

- Diabetes mellitus and acute myocardial infarction: more data supporting a poorer microvasculature reperfusion (Moreno et al). 2003;146:e6
- Don't shoot the messenger: the 6-minute walk test is a useful outcome measure in exercise trials (Witham and McMurdo). 2003;146:e7
- Hiccup as an electrocardiographic artifact simulating arrhythmias (Cheng) (Letter); (Márquez and Pastelín) (Reply). 2003;146:e15, e16
- Is left atrial appendage occlusion during routine coronary artery bypass graft surgery useful for stroke prevention? (Stöhlberger et al). 2003;146:e26
- Left bundle branch block is not equivalent to "absent septal q wave" (Spodick). 2003;146:e9
- Measurement of the effect of ticlopidine with the platelet function analyser (PFA-100) during coronary stent implantation (Fattorutto). 2003;146:e8
- Mibefradil: "has the baby been thrown out with the bath water?" (Beltrame et al). 2003;146:e3
- Therapeutic strategy in atrial fibrillation (Fauchier and Fauchier) (Letter); (AFFIRM Investigators) (Reply). 2003;146:e24, e25

Leukocyte count

- Preprocedural white blood cell count and death after percutaneous coronary intervention (Gurm et al). 2003;146:692-8

Lipids and Lipoproteins

- Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHES) (Ballantyne et al). 2003;146:862-9
- Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS) (Shlipak et al). 2003;146:870-5
- Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol (Bersot et al). 2003;146:1052-60
- Role of lipid and lipoprotein profiles in risk assessment and

therapy (Ballantyne and Hoogeveen). 2003;146:227-33 (Progress cardiol.)

- The cholesteryl ester transfer protein *Taq1B* gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease (Carlquist et al). 2003;146:1007-14

Lisinopril

- Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure (De Tommasi et al). 2003;146:e17

Losartan

- Choice of treatment: outcomes and treatment goals (Temple). 2003;146:565-7 (Editorial)
- Of millimeterology and cannibalism: comparative antihypertensive efficacy of angiotensin receptor blockers (Messeri). 2003;146:568-9 (Editorial)

M**Magnetic resonance imaging**

- Does the type of prosthesis influence early left ventricular mass regression after aortic valve replacement? Assessment with magnetic resonance imaging (Sensky et al). 2003;146:e13
- Nonstress delayed-enhancement magnetic resonance imaging of the myocardium predicts improvement of function after revascularization for chronic ischemic heart disease with left ventricular dysfunction (Schvartzman et al). 2003;146:535-41
- Quantitative clinical assessment of chronic anterior myocardial infarction with delayed enhancement magnetic resonance imaging and QRS scoring (Engblom et al). 2003;146:359-66

Mass screening

- Assessing risk for coronary heart disease: beyond Framingham (Cobb et al). 2003;146:572-80 (Editorial)
- Screening for early detection of cardiovascular disease in asymptomatic individuals (Cohn et al). 2003;146:679-85
- Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure (Baker et al). 2003;146:736-40
- Screening for structural heart disease: time to stop listening and start looking (Alexander and Patel). 2003;146:570-1 (Editorial)

Metabolic syndrome X

- Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial (Hsia et al). 2003;146:439-45

Metoprolol

- Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF (Jánosi et al). 2003;146:721-8

Mibefradil

- Mibefradil: "has the baby been thrown out with the bath water?" (Beltrame et al). 2003;146:e3 (Letter)

Mitral valve diseases; see Heart valve diseases**Monitoring, ambulatory**

- Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial (Goldberg et al). 2003;146:705-12

Mortality; see also Death, sudden, cardiac

- Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease (Mozaffarian et al). 2003;146:1015-22
- Does race matter in heart failure? (Yancy). 2003;146:203-6 (Editorial)
- Is heart failure survival improving? Evidence from 2323 elderly patients hospitalized between 1989-2000 (Feinglass et al). 2003;146:111-14
- Mortality trends for 23,505 Medicare patients hospitalized with

- heart failure in Northeast Ohio, 1991 to 1997 (Baker et al). 2003;146:258-64
- Obesity and the risk of early and late mortality after coronary artery bypass graft surgery (Kim et al). 2003;146:555-60
- Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction (Kerzner et al). 2003;146:286-90
- Racial disparity in long-term mortality rate after hospitalization for myocardial infarction: the Atherosclerosis Risk in Communities study (Ding et al). 2003;146:459-64
- Survival rates are similar between African American and white patients with heart failure (Dunlap et al). 2003;146:265-72
- MRI; see Magnetic resonance imaging**
- Myocardial infarction**
- Arg389Gly polymorphism of the human β 1-adrenergic receptor in patients with nonfatal acute myocardial infarction (Iwai et al). 2003;146:106-9
- Clinical and angiographic characteristics of patients with combined anterior and inferior ST-segment elevation on the initial electrocardiogram during acute myocardial infarction (Sadanandan et al). 2003;146:653-61
- Cognitive and somatic symptoms of depression are associated with medical comorbidity in patients after acute myocardial infarction (Watkins et al). 2003;146:48-54
- Joint effects of *Chlamydia pneumoniae* infection and classic coronary risk factors on risk of acute myocardial infarction (Kinjo et al). 2003;146:324-30
- Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction (Miyamoto et al). 2003;146:465-71
- Risk factors for myocardial infarction in Brazil (Piegas et al). 2003;146:331-8
- Myocardial infarction, diagnosis**
- A modified Anderson-Wilkins electrocardiographic acuteness score for anterior or inferior myocardial infarction (Hedén et al). 2003;146:797-803 (Curriculum cardiol.)
- Defining myocardial infarction: "Will the real myocardial infarction please stand up?" (Alpert). 2003;146:377-9 (Editorial)
- Impact of the troponin standard on the prevalence of acute myocardial infarction (Kontos et al). 2003;146:446-52
- Quantitative clinical assessment of chronic anterior myocardial infarction with delayed enhancement magnetic resonance imaging and QRS scoring (Engblom et al). 2003;146:359-66
- Myocardial infarction, drug therapy**
- A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (Amp579 Delivery for Myocardial Infarction REduction) study (Kopecky et al). 2003;146:146-52
- Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the Thrombolysis In Myocardial Infarction (TIMI) 14 trial (Murphy et al). 2003;146:42-7
- Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAM) trial (Latini et al). 2003;146:e2
- Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II) (Armstrong et al). 2003;146:484-8
- Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study) (Huynh et al). 2003;146:668-73
- Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines (Antman). 2003;146:S18-22
- One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction (Sinnaeve et al). 2003;146:27-32
- Prehospital thrombolysis with reteplase: the Nijmegen/Rotterdam study (Lamfers et al). 2003;146:479-83
- Myocardial infarction, prognosis**
- Association of the PURSUIT risk score with predischARGE ejection fraction, angiographic severity of coronary artery disease, and mortality in a nonselected, community-based population with non-ST-elevation acute myocardial infarction (Brilakis et al). 2003;146:811-18
- Baseline comorbidities and treatment strategy in elderly patients are associated with outcome of cardiogenic shock in a community-based population (Tedesco et al). 2003;146:472-8
- Diabetes mellitus and acute myocardial infarction: more data supporting a poorer microvasculature reperfusion (Moreno et al). 2003;146:e6 (Letter)
- Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy (Lockwood et al). 2003;146:640-5
- Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction (Ishihara et al). 2003;146:674-8
- New insight into clinical risk scores for patients with acute coronary syndromes (Morrow). 2003;146:754-6 (Editorial)
- Racial disparity in long-term mortality rate after hospitalization for myocardial infarction: the Atherosclerosis Risk in Communities study (Ding et al). 2003;146:459-64
- Sex differences in survival after acute myocardial infarction in patients with diabetes mellitus (Worcester Heart Attack Study) (Crowley et al). 2003;146:824-31
- Myocardial infarction, therapy**
- Are some patients in Canada treated more equally than others? The Orwell prophecy (Alter). 2003;146:938-40 (Editorial)
- Comparison of treatment and outcomes for patients with acute myocardial infarction in Minneapolis/St. Paul, Minnesota, and Göteborg, Sweden (Herlitz et al). 2003;146:1023-9
- Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies (Waters et al). 2003;146:958-68 (Curriculum cardiol.)
- Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2) (Andersen et al). 2003;146:234-41 (Trial design)
- Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase (Berrocal et al). 2003;146:e22
- Is geography destiny? Illuminating the survival advantage of elderly patients in New England after acute myocardial infarction (Ayanian). 2003;146:207-9 (Editorial)
- "Mirror-lake" serial relationship of electrocardiographic and biochemical indices for the detection of reperfusion and the prediction of salvage in patients with acute myocardial infarction (Jurlander et al). 2003;146:757-63 (Progress cardiol.)
- Noninvasive assessment of reperfusion therapy: slow progress toward a worthwhile goal (de Lemos and Morrow). 2003;146:747-9 (Editorial)
- Primary percutaneous transluminal coronary angioplasty accelerates early myocardial reperfusion compared to thrombolytic therapy in patients with acute myocardial infarction (Zeymer et al). 2003;146:686-91
- Regional variation in the treatment and outcomes of myocardial infarction: investigating New England's advantage (Krumholz et al). 2003;146:242-9
- Universal health insurance coverage does not eliminate inequi-

ties in access to cardiac procedures after acute myocardial infarction (Pilote et al). 2003;146:1030-7

Myocardial ischemia

- Acute coronary syndromes in patients with prior cerebrovascular events: lessons from the Euro-Heart Survey of Acute Coronary Syndromes (Hasdai et al). 2003;146:832-8
- Biphasic relaxation-frequency relations in patients with effort angina pectoris: a new marker of myocardial demand ischemia (Umeda et al). 2003;146:75-83
- Changing the model of care for patients with acute coronary syndromes (Roe et al). 2003;146:605-12 (Progress cardiol.)
- Depression and increased myocardial ischemic activity in patients with ischemic heart disease (Jiang et al). 2003;146:55-61
- Impact of angina burden and other factors on treatment satisfaction after acute coronary syndromes (Beinart et al). 2003;146:646-52
- Improved myocardial performance during repetitive exercise testing: the role of extracellular superoxide dismutase activity in a model of exercise-induced myocardial preconditioning (Michaelides et al). 2003;146:160-7
- Nonstress delayed-enhancement magnetic resonance imaging of the myocardium predicts improvement of function after revascularization for chronic ischemic heart disease with left ventricular dysfunction (Schvartzman et al). 2003;146:535-41

Myocardial ischemia, drug therapy

- A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes (Roe et al). 2003;146:993-8
- Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study (Ferguson et al). 2003;146:628-34
- Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where? (Lincoff). 2003;146:S23-30
- Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial (Michalis et al). 2003;146:304-10
- Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE) (Budaj et al). 2003;146:999-1006
- Low molecular weight heparins for acute coronary syndrome: tackling the issues head-on (Antman). 2003;146:191-3 (Editorial)
- Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention (Januzzi et al). 2003;146:764-74 (Curriculum cardiol.)
- Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy (Fragasso et al). 2003;146:e18

Myocardial reperfusion

- Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies (Waters et al). 2003;146:958-68 (Curriculum cardiol.)
- Diabetes mellitus and acute myocardial infarction: more data supporting a poorer microvasculature reperfusion (Moreno et al). 2003;146:e6 (Letter)
- Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase (Berrocal et al). 2003;146:e22
- "Mirror-lake" serial relationship of electrocardiographic and biochemical indices for the detection of reperfusion and the prediction of salvage in patients with acute myocardial infarction (Jurlander et al). 2003;146:757-63 (Progress cardiol.)

Noninvasive assessment of reperfusion therapy: slow progress toward a worthwhile goal (de Lemos and Morrow). 2003;146:747-9 (Editorial)

Primary percutaneous transluminal coronary angioplasty accelerates early myocardial reperfusion compared to thrombolytic therapy in patients with acute myocardial infarction (Zeymer et al). 2003;146:686-91

Myocardial revascularization

- Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention (Muhlestein et al). 2003;146:351-8
- Intracoronary brachytherapy for the prevention of restenosis after percutaneous coronary revascularization (Sheppard et al). 2003;146:775-86 (Curriculum cardiol.)
- Percutaneous coronary interventions in patients with renal insufficiency: a high-risk, under-studied cohort (Steinhubl). 2003;146:213-14 (Editorial)
- Preprocedural white blood cell count and death after percutaneous coronary intervention (Gurm et al). 2003;146:692-8
- Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis (Bourque et al). 2003;146:621-7
- Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions (Best et al). 2003;146:345-50
- Safety of same-day-discharge radial percutaneous coronary intervention: a retrospective study (Ziakas et al). 2003;146:699-704
- Subclinical diabetes mellitus: is it really "sub-clinical"? (Keebler and McGuire). 2003;146:210-12 (Editorial)

N

Natriuretic peptide, brain

Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure (Isnard et al). 2003;146:729-35

Neoplasms

Cardiac papillary fibroelastoma: a comprehensive analysis of 725 cases (Gowda et al). 2003;146:404-10 (Curriculum cardiol.)

Neopterin

Neopterin levels in patients with coronary artery disease are independent of *Chlamydia pneumoniae* seropositivity (Smith et al). 2003;146:69-74

Neurotransmitters

Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine (Wijesundera et al). 2003;146:291-7

Nitroglycerin

Effect of transdermal nitroglycerin on inflammatory mediators in patients with peripheral atherosclerotic vascular disease (Berrazuela et al). 2003;146:e14

O

Obesity

- Obesity and the risk of early and late mortality after coronary artery bypass graft surgery (Kim et al). 2003;146:555-60
- Reduction in obesity and coronary risk factors after high caloric exercise training in overweight coronary patients (Savage et al). 2003;146:317-23
- Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies (Spinler et al). 2003;146:33-41

Oxidative stress

- Endothelial dysfunction: clinical strategies for treating oxidant stress (Fenster et al). 2003;146:218-26 (Curriculum cardiol.)
- Improvement of peripheral endothelial dysfunction by acute vitamin C application: different effects in patients with coronary artery disease, ischemic, and dilated cardiomyopathy (Erbs et al). 2003;146:280-5
- Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine (Wijesundera et al). 2003;146:291-7

Oxygen consumption

- Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure (Isnard et al). 2003;146:729-35

P

Pacemaker, artificial

- Biphasic relaxation-frequency relations in patients with effort angina pectoris: a new marker of myocardial demand ischemia (Umeda et al). 2003;146:75-83
- Death in patients with permanent pacemakers for sick sinus syndrome (Flaker et al). 2003;146:887-93
- Endocardial pacemaker or defibrillator leads with infected vegetations: a single-center experience and consequences of transvenous extraction (Meier-Ewert et al). 2003;146:339-44
- Pacemaker therapy in very elderly patients: long-term survival and prognostic parameters (Schmidt et al). 2003;146:908-13
- Pacing in elderly patients (Jahangir and Shen). 2003;146:750-3 (Editorial)
- Worldwide evaluation of a defibrillation lead with a small geometric electrode surface for high-impedance pacing (Vollmann et al). 2003;146:1066-70

Patient discharge

- Safety of same-day-discharge radial percutaneous coronary intervention: a retrospective study (Ziakas et al). 2003;146:699-704

Patient satisfaction

- Impact of angina burden and other factors on treatment satisfaction after acute coronary syndromes (Beinart et al). 2003;146:646-52

Percutaneous coronary intervention; see Angioplasty; Myocardial revascularization; Stents

Pharmacogenetics

- Where the rubber meets the road in pharmacogenetics: assessment of gene-environment interactions (Hauser and Allen). 2003;146:929-31 (Editorial)

Pioglitazone

- Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study (Takagi et al). 2003;146:e5

Placebos

- Hypertensive patients' willingness to participate in placebo-controlled trials: implications for recruitment efficiency (Halpern et al). 2003;146:985-92 (Trial design)
- Patients' willingness to participate in placebo-controlled trials of antihypertensive therapy (Al-Khatib and Biswas). 2003;146:944-5 (Editorial)

Platelet activation

- Platelet activation after stenting with heparin-coated versus noncoated stents (Gurbel and Bliden). 2003;146:e10

Platelet aggregation

- Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the PLavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial (Serebruany et al). 2003;146:713-20
- Measurement of the effect of ticlopidine with the platelet function analyser (PFA-100) during coronary stent implantation (Fattorutto). 2003;146:e8 (Letter)

- Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction (Miyamoto et al). 2003;146:465-71

Platelet aggregation inhibitors

- Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study (Ferguson et al). 2003;146:628-34
- Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future (Leon and Bakhai). 2003;146: S13-17
- Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study) (Huynh et al). 2003;146:668-73
- Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE) (Budaj et al). 2003;146:999-1006
- Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines (Antman). 2003;146: S18-22
- Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention (Januzzi et al). 2003;146:764-74 (Curriculum cardiol.)

Plethysmography

- Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude (Kuvin et al). 2003;146:168-74

Pregnancy-associated alpha-plasma protein

- Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment (tule et al). 2003;146:e21

Prognosis

- Hippocrates and prognosis in heart failure: the challenge of static and dynamic measurements (Ventura and Mehra). 2003;146:215-17 (Editorial)
- Serial versus isolated assessment of clinical and instrumental parameters in heart failure: prognostic and therapeutic implications (Grigioni et al). 2003;146:298-303

PTCA; see Angioplasty, transluminal, percutaneous coronary

Pulmonary ventilation

- Normalization for peak oxygen uptake increases the prognostic power of the ventilatory response to exercise in patients with chronic heart failure (Guazzi et al). 2003;146:542-8

Pyridostigmine

- Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure (Behling et al). 2003;146:494-500
- Heart rate variability in chronic heart failure: target for therapy? (Sueta). 2003;146:385-7 (Editorial)

Q

Quality of health care; see Health care quality, access, and evaluation

Quality of life

- Comparison of health-related quality-of-life outcomes of men and women after coronary artery bypass surgery through 1 year: findings from the POST CABG Biobehavioral Study (Lindquist et al). 2003;146:1038-44
- Thermal hydrotherapy improves quality of life and hemodynamic function in patients with chronic heart failure (Michalsen et al). 2003;146:e11
- Women and outcomes of coronary artery bypass surgery: do we have an answer? (Vaccarino). 2003;146:935-7 (Editorial)

R**Racial stocks**

Does race matter in heart failure? (Yancy). 2003;146:203-6 (Editorial)

Racial disparity in long-term mortality rate after hospitalization for myocardial infarction: the Atherosclerosis Risk in Communities study (Ding et al). 2003;146:459-64

Survival rates are similar between African American and white patients with heart failure (Dunlap et al). 2003;146:265-72

Receptors, adrenergic, beta-1

Arg389Gly polymorphism of the human β 1-adrenergic receptor in patients with nonfatal acute myocardial infarction (Iwai et al). 2003;146:106-9

Renal diseases; see Kidney diseases**Reperfusion, myocardial; see Myocardial reperfusion****Restenosis, coronary; see Coronary restenosis****Retepase**

Prehospital thrombolysis with reteplase: the Nijmegen/Rotterdam study (Lamfers et al). 2003;146:479-83

Risk assessment

Assessing risk for coronary heart disease: beyond Framingham (Cobb et al). 2003;146:572-80 (Editorial)

Association of the PURSUIT risk score with predischARGE ejection fraction, angiographic severity of coronary artery disease, and mortality in a nonselected, community-based population with non-ST-elevation acute myocardial infarction (Brilakis et al). 2003;146:811-18

New insight into clinical risk scores for patients with acute coronary syndromes (Morrow). 2003;146:754-6 (Editorial)

Risk factors for myocardial infarction in Brazil (Piegas et al). 2003;146:331-8

Role of lipid and lipoprotein profiles in risk assessment and therapy (Ballantyne and Hoogeveen). 2003;146:227-33 (Progress cardiol.)

Screening for early detection of cardiovascular disease in asymptomatic individuals (Cohn et al). 2003;146:679-85

Risk management

Evaluation of the dofetilide risk-management program (Allen LaPointe et al). 2003;146:894-901

Rofecoxib

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program (Weir et al). 2003;146:591-604 (Progress cardiol.)

Roxifiban

Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy) (Serebruany et al). 2003;146:91-8

S**Saphenous vein**

Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft (Leborgne et al). 2003;146:501-6

Screening; see Mass screening**Sex factors**

Comparison of health-related quality-of-life outcomes of men and women after coronary artery bypass surgery through 1 year: findings from the POST CABG Biobehavioral Study (Lindquist et al). 2003;146:1038-44

False-positive exercise echocardiograms: impact of sex and blood pressure response (Shin et al). 2003;146:914-19

Sex differences in survival after acute myocardial infarction in patients with diabetes mellitus (Worcester Heart Attack Study) (Crowley et al). 2003;146:824-31

Women and outcomes of coronary artery bypass surgery: do we have an answer? (Vaccaro). 2003;146:935-7 (Editorial)

Shock, cardiogenic

Baseline comorbidities and treatment strategy in elderly patients are associated with outcome of cardiogenic shock in a community-based population (Tedesco et al). 2003;146:472-8

Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on a 12-month survival in the SHOCK trial (French et al). 2003;146:804-10

Sick sinus syndrome

Death in patients with permanent pacemakers for sick sinus syndrome (Flaker et al). 2003;146:887-93

Simvastatin

Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS) (Ballantyne et al). 2003;146:862-9

Sphingolipids

Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate (Deutschman et al). 2003;146:62-8

Staphylokinase, recombinant

Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II) (Armstrong et al). 2003;146:484-8

Statins; see Hydroxymethylglutaryl-CoA reductase inhibitors**Statistics**

Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality (Gombert-Maitland et al). 2003;146:398-403 (Curriculum cardiol.)

Stem cells

Loss of bone marrow-derived vascular progenitor cells leads to inflammation and atherosclerosis (Goldschmidt-Clermont). 2003;146:S5-12

Stents

Additional stenting promotes intimal proliferation and compromises the results of intravascular radiation therapy: an intravascular ultrasound study (Cheneau et al). 2003;146:142-5

Analysis of the institutional volume-outcome relations for balloon angioplasty and stenting in the stent era in California (Brown). 2003;146:1071-6

Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future (Leon and Bakhai). 2003;146:S13-17

Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft (Leborgne et al). 2003;146:501-6

Effect of plaque debulking before stent implantation on in-stent neointimal proliferation: a serial 3-dimensional intravascular ultrasound study (Takeda et al). 2003;146:175-82

Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting (Massberg et al). 2003;146:e19

4G/5G Polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting (Böttiger et al). 2003;146:855-61

Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial (Hausleiter et al). 2003;146:882-6

Measurement of the effect of ticlopidine with the platelet function analyser (PFA-100) during coronary stent implantation (Fattorutto). 2003;146:e8 (Letter)

Percutaneous coronary intervention: historical perspectives, current status, and future directions (Arjomand et al). 2003;146:787-96 (Curriculum cardiol.)

Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study (Takagi et al). 2003;146:e5

Platelet activation after stenting with heparin-coated versus noncoated stents (Gurbel and Bliden). 2003;146:e10

- Prospective randomized comparison of early and late results of 4 different stent designs (Sick et al). 2003;146:134-41
- Restenosis in Intervened Coronaries with Hyperhomocysteinemia (RICH) (Kojouharian et al). 2003;146:1077-81
- Self- and balloon-expandable stent implantation for severe native coarctation of aorta in adults (Tyagi et al). 2003;146:920-8
- Serologic markers of persistent *Chlamydia pneumoniae* infection and long-term prognosis after successful coronary stenting (Zairis et al). 2003;146:1082-9
- Volume as a surrogate for percutaneous coronary intervention quality: is this the right measuring stick? (Brindis et al). 2003;146:932-4 (Editorial)
- Streptococcus agalactiae**
Clinical profile of *Streptococcus agalactiae* native valve endocarditis (Rollán et al). 2003;146:1095-8
- Streptokinase**
Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase (Berrocal et al). 2003;146:e22
- Stress, psychological**
Are heart rate and blood pressure responses to mental stress predictive of clinical cardiovascular events? The answer varies by coronary artery disease syndrome (Sheps and Bragdon). 2003;146:197-8 (Editorial)
- Heart rate and blood pressure responses to mental stress and clinical cardiovascular events in men and women after coronary artery bypass grafting: the Post Coronary Artery Bypass Graft (Post-CABG) biobehavioral study (Herd et al). 2003;146:273-9
- Stress test; see Echocardiography, stress; Exercise test**
- Stroke; see Cerebrovascular accident**
- Stroke volume**
Ejection fraction by echocardiography: the full monty or just a peep show? (Schiller). 2003;146:380-2 (Editorial)
- Prognostic implications of ejection fraction from linear echocardiographic dimensions: the Strong Heart Study (Devereux et al). 2003;146:527-34
- Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods (McGowan and Cleland). 2003;146:388-97 (Curriculum cardiol.)
- Sudden cardiac death; see Death, sudden, cardiac**
- Superoxide dismutase**
Improved myocardial performance during repetitive exercise testing: the role of extracellular superoxide dismutase activity in a model of exercise-induced myocardial preconditioning (Michaelides et al). 2003;146:160-7
- Survival rate; see Mortality**

T

- Tenecteplase**
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction (Sinnaeve et al). 2003;146:27-32
- Thioredoxin**
Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction (Miyamoto et al). 2003;146:465-71
- Thromboembolism; see Embolism and thrombosis**
- Thrombolytic therapy**
Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the Thrombolysis In Myocardial Infarction (TIMI) 14 trial (Murphy et al). 2003;146:42-7
- Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II) (Armstrong et al). 2003;146:484-8

- Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2) (Andersen et al). 2003;146:234-41 (Trial design)
- Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy (Lockwood et al). 2003;146:640-5
- Influence of thrombolytic therapy, with or without intra-aortic balloon counterpulsation, on a 12-month survival in the SHOCK trial (French et al). 2003;146:804-10
- One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction (Sinnaeve et al). 2003;146:27-32
- Prehospital thrombolysis with reteplase: the Nijmegen/Rotterdam study (Lamfers et al). 2003;146:679-83
- Primary percutaneous transluminal coronary angioplasty accelerates early myocardial reperfusion compared to thrombolytic therapy in patients with acute myocardial infarction (Zeymer et al). 2003;146:686-91

Ticlopidine

- Measurement of the effect of ticlopidine with the platelet function analyser (PFA-100) during coronary stent implantation (Fattorutto). 2003;146:e8 (Letter)

Tinzaparin

- Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial (Michalis et al). 2003;146:304-10

Tirofiban

- Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study) (Huynh et al). 2003;146:668-73
- Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting (Massberg et al). 2003;146:e19

Tissue Doppler imaging; see Echocardiography, Doppler Tomography, x-ray computed

- Electron beam CT versus helical CT scans for assessing coronary calcification: current utility and future directions (Nasir et al). 2003;146:969-77 (Progress cardiol.)

Tricuspid valve

- Right ventricular function before and after an uncomplicated coronary artery bypass graft as assessed by pulsed wave Doppler tissue imaging of the tricuspid annulus (Alam et al). 2003;146:520-6

Trimetazidine

- Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy (Fragasso et al). 2003;146:e18

Troponin

- Defining myocardial infarction: "Will the real myocardial infarction please stand up?" (Alpert). 2003;146:377-9 (Editorial)
- Impact of the troponin standard on the prevalence of acute myocardial infarction (Kontos et al). 2003;146:446-52

U

Ultrasonography, interventional

- Additional stenting promotes intimal proliferation and compromises the results of intravascular radiation therapy: an intravascular ultrasound study (Cheneau et al). 2003;146:142-5
- Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events (Ricciardi et al). 2003;146:507-12
- Effect of plaque debulking before stent implantation on in-stent neointimal proliferation: a serial 3-dimensional intravascular ultrasound study (Takeda et al). 2003;146:175-82
- Pioglitazone reduces neointimal tissue proliferation after coro-

nary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study (Takagi et al). 2003;146:e5

V

Valsartan

Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure (De Tommasi et al). 2003;146:e17

Vasopressins

Vasopressin: a new target for the treatment of heart failure (Lee et al). 2003;146:9-18 (Progress cardiol.)

Ventricular arrhythmias; see Arrhythmia

Ventricular dysfunction, left

Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction (Prasad et al). 2003;146:549-54

Left ventricular wall stress as a direct correlate of cardiomyocyte apoptosis in patients with severe dilated cardiomyopathy (Di Napoli et al). 2003;146:1105-11

Myocardial factor for timing of surgery in asymptomatic patients with mitral regurgitation (Stewart). 2003;146:5-8 (Editorial)

Nonstress delayed-enhancement magnetic resonance imaging of the myocardium predicts improvement of function after revascularization for chronic ischemic heart disease with left ventricular dysfunction (Schwartzman et al). 2003;146:535-41

Relationship of ventricular longitudinal function to contractile reserve in patients with mitral regurgitation (Haluska et al). 2003;146:183-8

Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis (Bourque et al). 2003;146:621-7

Screening for left ventricular systolic dysfunction among patients with risk factors for heart failure (Baker et al). 2003;146:736-40

Screening for structural heart disease: time to stop listening and start looking (Alexander and Patel). 2003;146:570-1 (Editorial)

Ventricular function, left

Clinical and angiographic characteristics of patients with combined anterior and inferior ST-segment elevation on the initial electrocardiogram during acute myocardial infarction (Sadanandan et al). 2003;146:653-61

Ejection fraction by echocardiography: the full monty or just a peep show? (Schiller). 2003;146:380-2 (Editorial)

Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction (Ishihara et al). 2003;146:674-8

Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function (Ansari et al). 2003;146:115-20

Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction (Kerzner et al). 2003;146:286-90

Prognostic implications of ejection fraction from linear echocardiographic dimensions: the Strong Heart Study (Devereux et al). 2003;146:527-34

Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods (McGowan and Cleland). 2003;146:388-97 (Curriculum cardiol.)

Spectral pulsed tissue Doppler imaging in diastole: a tool to increase our insight in and assessment of diastolic relaxation of the left ventricle (De Boeck et al). 2003;146:411-19 (Progress cardiol.)

Ventricular function, right

Right ventricular function before and after an uncomplicated coronary artery bypass graft as assessed by pulsed wave Doppler tissue imaging of the tricuspid annulus (Alam et al). 2003;146:520-6

Ventricular remodeling

Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAM) trial (Latini et al). 2003;146:e2

Does the type of prosthesis influence early left ventricular mass regression after aortic valve replacement? Assessment with magnetic resonance imaging (Sensky et al). 2003;146:e13

Vitamin C

Improvement of peripheral endothelial dysfunction by acute vitamin C application: different effects in patients with coronary artery disease, ischemic, and dilated cardiomyopathy (Erbs et al). 2003;146:280-5

Vocal cord paralysis

Vocal cord paralysis after transcatheter coil embolization of patent ductus arteriosus (Liang et al). 2003;146:367-71

W

Warfarin

Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V) (Halperin and SPORTIF Executive Steering Committee). 2003;146:431-8 (Trial design)

Weight; see Body weight

Women; see also Sex factors

Cardiac pathologic findings reveal a high rate of sudden cardiac death of undetermined etiology in younger women (Chugh et al). 2003;146:635-9

Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study) (Huynh et al). 2003;146:668-73

Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS) (Shlipak et al). 2003;146:870-5

Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial (Hsia et al). 2003;146:439-45

X

Ximelagatran

Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V) (Halperin and SPORTIF Executive Steering Committee). 2003;146:431-8 (Trial design)

